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Neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases, are characterised by the 
formation of aberrant assemblies of misfolded proteins. The discovery of disease-modifying drugs for these 
disorders is challenging, in part because we still have a limited understanding of their molecular origins. In 
this review, we discuss how biophysical approaches can help explain the formation of the aberrant 
conformational states of proteins whose neurotoxic effects underlie these diseases. We discuss in particular 
models based on the transgenic expression of amyloid-b (Ab) and tau in Alzheimer’s disease, and a-
synuclein in Parkinson’s disease. Since biophysical methods have enabled an accurate quantification and a 
detailed understanding of the molecular mechanisms underlying protein misfolding and aggregation in 
vitro, we expect that the further development of these methods to probe directly the corresponding 
mechanisms in vivo will open effective routes for diagnostic and therapeutic interventions. 
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Protein misfolding and aggregation are associated with a wide variety of human diseases (Hardy and 
Selkoe, 2002; Eisenberg and Jucker, 2012; Jucker and Walker, 2013; Knowles, Vendruscolo and Dobson, 
2014; Chiti and Dobson, 2017). These diseases have been linked to a progressive failure of the protein 
homeostasis system, which controls protein folding, trafficking and degradation (Balch et al., 2008; Kim et 
al., 2013). The capacity of this system has been shown to decline with age both in model organisms and in 
humans, which can result in the accumulation of aberrant protein aggregates (Labbadia and Morimoto, 
2015). Neurons appear to be particularly vulnerable to such events (Freer et al., 2016; Surmeier, Obeso and 
Halliday, 2017; Luna et al., 2018; Fu et al., 2019), and the vast majority of neurodegenerative diseases are 
accompanied by the formation of protein deposits, including those of amyloid-b (Ab) and tau in 
Alzheimer’s disease (AD), and of a-synuclein in Parkinson’s disease (PD) (Hardy and Selkoe, 2002; 
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Eisenberg and Jucker, 2012; Jucker and Walker, 2013; Knowles, Vendruscolo and Dobson, 2014; Chiti and 
Dobson, 2017). 
 
Whereas mature amyloid fibrils are in many cases relatively inert, studies in cell culture and animal models 
have revealed that misfolded oligomers, which are formed during the process of fibril formation, possess 
cytotoxic properties (Bucciantini et al., 2002; Baglioni et al., 2006; Haass and Selkoe, 2007; Bemporad and 
Chiti, 2012; Benilova, Karran and De Strooper, 2012; Chiti and Dobson, 2017). Several mechanisms have 
been proposed to account for the toxicity of these oligomers, including disruption of lipid membranes, 
transcriptional deregulation, mitochondrial dysfunction, oxidative stress, proteasome inhibition, and 
disruption of synaptic plasticity (Haass and Selkoe, 2007; Benilova, Karran and De Strooper, 2012; Roberts 
and Brown, 2015; De et al., 2019). Some of these mechanisms affect components of the protein homeostasis 
system, resulting in a collapse of protein quality control and a further increase in protein misfolding and 
toxicity (Labbadia and Morimoto, 2015). On the whole, however, the molecular mechanisms whereby 
protein misfolding gives rise to toxicity are not yet understood to the extent needed to enable the 
development of disease-modifying treatments for the vast majority of these disorders.  
 
In this context, in vivo models can both increase our understanding of the mechanisms of disease and 
provide a platform for drug screening and preclinical development (Dawson, Golde and Lagier-Tourenne, 
2018; Götz, Bodea and Goedert, 2018). A variety of model organisms has been exploited to probe protein 
misfolding diseases, ranging from simple unicellular systems such as yeast, to more complex ones such as 
rodents and primates. Simple organisms lack specific aspects of human biology, but can be faster and more 
cost-effective to work with, making them particularly suitable for high-throughput screens, and for the study 
of highly conserved cellular pathways (Khurana and Lindquist, 2010; Rincon-Limas, Jensen and 
Fernandez-Funez, 2012; Sin, Michels and Nollen, 2014). More complex organisms can recapitulate human 
disease phenotypes better, and are typically used in preclinical studies to examine efficacy and safety prior 
to testing in humans (Jucker, 2010; Sasaguri et al., 2017). 
 
In general, in vivo models of disease can be studied at different levels. Organismal and cellular phenotypes 
can be related to the aggregation states of disease-associated proteins at the molecular level by biochemical 
and biophysical tools (Table 1). Correspondingly, at the systems level, disrupted molecular pathways can 
be comprehensively monitored by genomics, transcriptomics and proteomics techniques [Barabási, Albert-
László, Natali Gulbahce, and Joseph Loscalzo. "Network medicine: a network-based approach to human 
disease." Nature reviews genetics 12.1 (2011): 56-68]. With these approaches, the association of a 
perturbation (e.g. the expression of a mutant gene) with a phenotype (i.e. an aspect of the disease) is 
 5 
translated into a knowledge of specific biochemical processes associated with the disease under 
investigation. Finally, comparison with in vitro studies can contribute to deciphering the molecular 
mechanisms of these processes, and represents a powerful strategy for revealing the molecular origins of a 
disease, and for identifying possible targets for therapeutic interventions (Knowles, Vendruscolo and 
Dobson, 2014; Chiti and Dobson, 2017). 
 
Here, we provide an overview of the analysis of protein misfolding in transgenic models of AD and PD 
based on the transgenic expression of amyloid-b (Ab) or tau, and of a-synuclein, respectively. We 
furthermore discuss methodological challenges in developing biophysical tools to probe in vivo the 
aggregation process and the resulting aggregate species, which are required to provide quantitative 
assessments of cause-effect relationships in disease and of the efficacy of potential therapies.  
 
 
2. Determination of protein aggregation mechanisms using in vitro biophysical methods  
 
Biophysical studies of protein aggregation in vitro enable the identification of possible molecular 
mechanisms of protein aggregation in vivo and the corresponding neurodegenerative processes (Knowles, 
Vendruscolo and Dobson, 2014; Chiti and Dobson, 2017). This approach is powerful not only because in 
vitro systems are amenable to a wider range of technologies compared to in vivo systems (Table 1) but also 
because experimental conditions can be carefully controlled, and the effects of specific perturbations can 
be examined, e.g. with the introduction of cellular components whose relevance has been revealed by in 
vivo studies. 
 
In particular, the kinetics of the protein aggregation process can be measured quantitatively in vitro, leading 
to detailed mechanistic understanding of the process itself. Protein aggregation over time is typically 
monitored by measuring the fluorescence of the amyloid-sensitive dye thioflavin T (ThT). The analysis of 
the concentration dependence of the time courses of the ThT signal leads to a description of the microscopic 
steps in the aggregation process and the associated rate constants (Figure 1A) (Knowles et al., 2009; Cohen 
et al., 2012; Meisl, Kirkegaard, et al., 2016; Michaels et al., 2017). Aggregation reactions that start from 
purely monomeric species require primary nucleation events, which involve the assembly of some 
monomers into disordered oligomers, which can then undergo a structural conversion into forms  that have 
the capacity to grow by elongation through the addition of more monomers [Michaels, T.C.T., Šarić, A., 
Curk, S. et al. Dynamics of oligomer populations formed during the aggregation of Alzheimer’s Aβ42 
peptide. Nat. Chem. (2020). https://doi.org/10.1038/s41557-020-0452-1]. When fibrils are formed, 
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secondary processes play a significant role in a variety of systems, and in some cases can dominate the 
overall aggregation behaviour (S. I. A. Cohen et al., 2013) (Meisl et al., 2014). These processes are 
dependent on the concentration of the existing amyloid aggregates, and include fibril fragmentation as well 
as secondary nucleation of monomers on fibril surfaces (Figure 1B). Secondary processes represent a feed-
forward loop and cause an exponential proliferation of fibrils (S. I. A. Cohen et al., 2013) (Meisl et al., 
2014). It is of great importance to understand the relative contributions of the microscopic steps underlying 
the aggregation process in the context of disease, especially given that potentially toxic oligomers may arise 
from both primary and secondary nucleation. 
 
We present here recent insights obtained from in vitro experiments on the aggregation mechanisms of Ab, 
tau and a-synuclein, in particular those that can be correlated directly with observations made in in vivo 
models.  
 
2.1 Ab aggregation 
The aggregation of Ab into extracellular amyloid plaques is a hallmark of both the familial (early-onset) 
and sporadic (late-onset) forms of AD. The involvement of amyloid precursor protein (APP) and its 
sequential processing into Ab by b-secretase and g-secretase (Figure 2A) is well established through the 
amyloid hypothesis (Selkoe and Hardy, 2016). In particular, mutations in APP or in the presenilin (PSEN) 
subunit of g-secretase are directly linked to familial forms of the disease, and triplication of chromosome 
21, on which the APP gene is located, is associated with the development of AD in patients with Down 
syndrome (Karran and De Strooper, 2016; Selkoe and Hardy, 2016). The relationship between Ab 
aggregation and the onset and progression of AD has been debated extensively (Herrup, 2015; Karran and 
De Strooper, 2016; Selkoe and Hardy, 2016), with studies suggesting that amyloid deposition may precede 
the onset of symptoms (Bateman et al., 2012; Jack et al., 2013; Villemagne et al., 2013), and supporting a 
relationship between Ab oligomers and cellular toxicity (Benilova, Karran and De Strooper, 2012; Chiti 
and Dobson, 2017).  
 
Several Ab variants of different lengths and with different post-translational modifications exists in the 
human brain, with the two most common forms being of 40 (Ab40) and 42 (Ab42) residues (Kummer and 
Heneka, 2014). Studying in vitro the aggregation of these different forms of Ab, in particular with respect 
to oligomer formation, has led to the establishment of correlations between aggregation mechanisms and 
cytotoxic processes, in particular by revealing the importance of secondary nucleation in the proliferation 
of the aggregates (S. I. A. Cohen et al., 2013) (Meisl et al., 2014) (Figure 1A,B). Ab42 aggregates faster 
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than Ab40 in vitro, with the relative contributions of the microscopic aggregation steps being differerent 
for the two isoforms, as in particular the rate of primary nucleation is enhanced for Ab42 (Meisl et al., 
2014). From in vitro studies, it has furthermore become clear that the two forms can affect the behaviour 
of each other, although the details of such interplay still remain unclear (Pauwels et al., 2012; Yu-Jen and 
Yun-Ru, 2014; Cukalevski et al., 2015; Tran et al., 2017).  
 
Familial mutations linked to early-onset AD include those in the presenilins that affect the cleavage of Ab, 
leading to increased levels of Ab42 in particular. However, some mutations also occur within the Ab 
sequence itself, and these have been found to cause increased aggregation propensities (see 
www.alzforum.org/mutations). A study expressing a series of Ab42 mutants in Drosophila has found a 
remarkable correlation between the in vitro aggregation rates of the variants and measures of cytotoxicity, 
namely reduced locomotor function and lifespan, as described below in Section 3.1 (Luheshi et al., 2007). 
Using in vitro assays, further mechanistic insights have been obtained to probe which of the microscopic 
steps in the aggregation process are affected for the Ab42 variants. For example, for the A2V Ab42 mutant 
associated with early-onset AD, it has been shown that secondary nucleation is significantly enhanced 
compared to that observed for the wild-type form, potentially generating a larger flux of toxic oligomers 
(Meisl, Yang, et al., 2016). In addition, mutations of residues E22 and D23, which are surface-exposed, 
have been found to lead to enhanced secondary nucleation, whereas the elongation rates are close to that of 
the wild-type peptide (Yang et al., 2018). Although the aggregation process may be affected by extrinsic 
factors in vivo, these findings suggest that the surface properties of Ab fibrils play an important role in the 
generation of toxicity. 
 
Given the cytotoxicity of the oligomeric forms of Ab (Bucciantini et al., 2002; Baglioni et al., 2006; Haass 
and Selkoe, 2007; Bemporad and Chiti, 2012; Benilova, Karran and De Strooper, 2012; Chiti and Dobson, 
2017), the structural features of these assemblies are under close investigation. Characterisation of a 
particular form of such oligomers by solid-state NMR spectroscopy (Table 1) has provided evidence for 
parallel b-sheet content (Parthasarathy et al., 2015). Other structural studies on samples prepared in vitro 
have provided evidence for the existence of more loosely packed Ab42 oligomers (Ahmed et al., 2010), as 
well as antiparallel b-sheet oligomers (Cerf et al., 2009; Stroud et al., 2012; Huang et al., 2015). A structural 
study of Ab40 oligomers stabilised by zinc ions has also revealed a compresence of both parallel and 
antiparallel b-sheet conformations (Mannini et al., 2018). Mature Ab42 fibrils, on the other hand, have only 
ever been found to adopt parallel b-sheet conformations as evidenced by recent structure determination 
using solid-state NMR spectroscopy (Xiao et al., 2015; Colvin et al., 2016; Wälti et al., 2016) and cryo-
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electron microscopy (cryo-EM, Table 1) (Gremer et al., 2017). A conformational mapping of Ab42 
oligomers using a panel of single-domain antibodies rationally designed to scan the whole Ab42 sequence 
(Aprile et al., 2017) has revealed that early oligomers produced during the aggregation reaction are 
structurally different from those produced at later stages, and correspondingly are toxic through different 
mechanisms (De et al., 2019). 
 
Lipid membranes are likely to play a central role in the aggregation process of Ab in vivo, given that the 
peptide is generated from the cleavage of APP within lipid bilayers. As such, aggregation is likely to occur 
in the vicinity of these membranes, whether intracellularly within endosomes or lysosomes, or 
extracellularly near the plasma membrane. Depending on the types of lipids and the fluidity of the 
membranes, studies of synthetic liposomes in in vitro aggregation reactions of Ab have led to a wide range 
of different results. Lipids in a gel phase have been found to have a stronger inhibitory effect on Ab 
aggregation kinetics than those in liquid-crystalline bilayers (Hellstrand, Sparr and Linse, 2010). 
Furthermore, a relationship may exist between the levels of cholesterol and Ab deposition, as the major risk 
factor for late-onset AD, the presence of a mutation in the ApoE gene, is involved in cholesterol metabolism 
(Mahley, 1988). Incorporating cholesterol in lipid vesicles in aggregation assays has revealed that 
cholesterol does indeed promote Ab42 aggregation (Habchi et al., 2018). This effect could be due to the 
fact that cholesterol modifies the fluidity of the membrane, although a direct molecular interaction between 
cholesterol and Ab42 has also been reported (Di Scala et al., 2014). Studying the effects of the lipid 
membrane composition and fluidity in more detail will be important as these properties may be altered 
during ageing and neurodegeneration, e.g. as a consequence of lipid oxidation, which not only modifies the 
lipid types but also reduces membrane fluidity (Borst et al., 2000). 
 
2.2 Tau aggregation 
Intracellular neurofibrillary tangles composed of hyperphosphorylated tau are a hallmark of AD, along with 
the presence of extracellular amyloid plaques. Tau deposits are observed in a family of neurodegenerative 
disorders collectively known as tauopathies, which in addition to AD include Pick’s disease, corticobasal 
degeneration, progressive supranuclear palsy, argyrophilic grain disease and frontotemporal dementia (Lee, 
Goedert and Trojanowski, 2001). In the human brain, the MAPT gene encoding tau undergoes alternative 
splicing leading to six possible isoforms, depending on the number of N-terminal insertions (0N, 1N, or 
2N) and microtubule binding repeats (3R or 4R) (Figure 2B) (Goedert et al., 1989). Mutations in MAPT 
are associated with the development of several tauopathies, although specific mutations have not been 
reported for AD patients. 
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Tau was originally described as a protein that binds and stabilises microtubules (Weingarten et al., 1975). 
It is intrinsically disordered in its monomeric form, and has several phosphorylation sites which can be 
modified to regulate microtubule stability, with hyperphosphorylation being associated with disease (Wang 
and Mandelkow, 2016). The classical histopathological staging of the disease (Braak and Braak, 1991), as 
well as recent advances in positron emission tomography (PET) imaging have revealed that tau deposition 
is more closely related to the symptoms of AD than is the presence of amyloid plaques (Ossenkoppele et 
al., 2016; Tosun et al., 2017; Xia et al., 2017). However, the mechanisms by which tau causes cellular 
toxicity are not fully understood, and the relationship with Ab accumulation is still under debate (Spires-
Jones and Hyman, 2014). 
 
The C-terminal region of tau contains the microtubule binding repeats, which include the short hexapeptide 
stretches VQIINK and VQIVYK that have a high propensity to form b-strands and are essential for the 
aggregation of tau (Wang and Mandelkow, 2016). Tau is highly hydrophilic and intrinsically disordered, 
although it has been shown to adopt preferentially a compact conformation in which the N- and C-terminal 
regions are in close proximity (Jeganathan et al., 2006). The N-terminal part of tau is known as the 
projection domain, extending away from the interaction site when tau is bound to microtubules, and away 
from the fibril surface in the case of fibrillar tau. Given that truncated versions of tau, or constructs 
comprising only the C-terminal repeat region, have increased aggregation propensity, the N-terminal region 
is thought to exert a protective effect (Wang and Mandelkow, 2016). Under typical in vitro conditions, 
however, tau does not aggregate spontaneously, but to form fibrils requires the addition of catalysts, as for 
example poly-anionic molecules such as heparin. The negative charges may be required to overcome the 
repulsion between tau molecules, each of which carries a net positive charge in the C-terminal repeat region, 
although heparin also induces the aggregation of phosphorylated tau with a net negative charge by an 
unknown mechanism (Wang and Mandelkow, 2016). 
 
In vitro studies have been instrumental in complementing in vivo work to shed light on the role of familial 
mutations, splicing and phosphorylation in tau aggregation and toxicity. A key finding has been that 
disease-associated mutations reduce the affinity of tau for microtubules, which may increase the risk of 
aggregation in vivo as the same region of the protein is involved in both processes (Hong et al., 1998). The 
six tau isoforms have been shown to vary in their aggregation propensity, with the 4R isoforms being more 
aggregation-prone than the 3R isoforms (Zhong et al., 2012). How this finding relates to pathological 
conditions is unclear, however, as in AD a mixture of 3R and 4R isoforms is found in tau tangles, whereas 
in other tauopathies such as Pick’s disease and agyrophilic grain disease either the 3R or 4R tau species 
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dominates. A potential explanation could again be provided by post-translational modifications such as 
phosphorylation. Out of the 85 theoretical phosphorylation sites in the tau sequence, about 45 have been 
observed in tau derived from AD brains (Hanger, Anderton and Noble, 2009). In vitro assays have led to 
the identification of the potential kinases and phosphatases associated with various sites, and for example 
GSK-3 has been found to be capable of targeting many sites (Hanger, Anderton and Noble, 2009), 
consistent with its important role in tau toxicity as observed in a variety of animal models as outlined in 
Section 3.2. In the light of the complex patterns of phosphorylation, it is not surprising that conflicting 
results have been obtained on whether hyperphosphorylation of tau promotes or inhibits its aggregation. 
Hyperphosphorylated tau extracted from AD brains is able to form fibrils in vitro, whereas 
dephosphorylation using alkaline phosphatase inhibits aggregation into fibrils (Alonso et al., 2001). 
Conversely, pseudo-phosphorylated constructs comprising the tau repeat region show much slower 
aggregation in vitro, although they may result in the formation of a larger number of oligomers (Kumar et 
al., 2014). 
 
Directly and quantitatively observing the formation of oligomeric species has been challenging due to their 
heterogeneous and transient nature, but an elegant single-molecule Förster resonance energy transfer 
(smFRET, Table 1) assay has yielded important insights into the generation of tau oligomers (Shammas et 
al., 2015). In this assay, relatively small oligomers were detected early in the aggregation process and these 
were found to subsequently convert into fibrils. The familial mutants ∆K280 and P301L were not only 
observed to aggregate faster, but also to form a larger population of oligomers than the wild-type protein, 
the oligomers being of the same apparent size. An anti-aggregation mutant with two proline substitutions 
that is less toxic in mouse models (Eckermann et al., 2007; Mocanu et al., 2008) was also found to form 
oligomers, however. Thus, the levels of oligomeric species cannot be directly correlated with toxicity, 
presumably because the mutations lead to oligomers with distinct structural characteristics (Shammas et 
al., 2015). In a follow-up study, different types of oligomers could be distinguished by varying the buffer 
conditions in the smFRET system (Kjaergaard et al., 2018). One type was found to be sensitive to the ionic 
strength of the buffer, and to be in rapid exchange with tau monomers, whereas the other type was found 
to be more stable and presumably unable to convert to fibrils (Kjaergaard et al., 2018). Both species may 
be toxic, but it is likely that they operate via different mechanisms. 
 
Recently, liquid-liquid phase separation has attracted attention as a biophysical phenomenon that may act 
as a precursor to the aggregation of several disease-related proteins (Shin and Brangwynne, 2017; Alberti 
and Dormann, 2019). Also the repeat region of tau has been found to condense into liquid droplets in vitro, 
depending on parameters such as the protein concentration, pH value and temperature (Ambadipudi et al., 
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2017). Phase separation has been observed to induce reversibly the formation of b-strands as detected by 
circular dichroism (CD, Table 1) spectroscopy. The absence of ThT fluorescence suggests that the phase-
separated state does not consist of amyloid fibrils, however, although the addition of heparin to the droplets 
was found to induce amyloid-like aggregation. NMR spectroscopy (Table 1) has furthermore shown that 
the conformation of tau is not drastically altered in the phase-separated state, whereas paramagnetic 
relaxation experiments and 13C-detected experiments have provided evidence for involvement of the repeat 
regions and the hexapeptide motifs (Ambadipudi et al., 2017, 2019). 
 
Full-length, phosphorylated tau has also been found to phase separate under physiological conditions and 
to form droplets both in vitro and in neuronal cells in culture (Wegmann et al., 2018). The process has been 
suggested to be mediated by weak hydrophobic interactions between the hexapeptide repeats, as the liquid 
droplets were observed to be sensitive to dissociation by urea and by 1,6-hexanediol. The N-terminal region 
of tau by itself was also observed to phase separate, but in this case driven by electrostatic interactions that 
can be disrupted by salt. The importance of electrostatics is further underscored by the effect of tau 
phosphorylation, which was shown to be required for efficient droplet formation. Finally, tau liquid droplets 
were found to convert rapidly into gels, and after prolonged incubation into non-spherical ThS positive 
aggregates, confirming that tau phase separation can be on pathway to aggregate formation (Wegmann et 
al., 2018). Whether phase separation drives tau aggregation in human disease remains to be determined, 
and it will be exciting to study this phenomenon in in vivo models, e.g. by using fluorescence lifetime 
imaging microscopy (FLIM, Table 1) in C. elegans (Laine et al., 2019) (see Section 3.4). 
 
2.3 a-Synuclein aggregation 
The 140-residue protein a-synuclein (Figure 2C) is the major component of the insoluble intracellular 
deposits known as Lewy bodies and Lewy neurites that are characteristically found in the brains of PD 
patients, as well as in those suffering from dementia with Lewy bodies (DLB) (Spillantini, R. A. Crowther, 
Jakes, Hasegawa, et al., 1998) and multiple systems atrophy (MSA) (Spillantini, R. A. Crowther, Jakes, 
Cairns, et al., 1998), a set of diseases collectively termed synucleinopathies. PD is associated with the 
specific loss of dopaminergic neurons in the substantia nigra, which results in impaired motor function, as 
well as a variety of other deficits including behavioural changes, sleep problems, and a diminished sense 
of smell. Gene duplications and triplications and several point mutations in the SNCA gene, encoding a-
synuclein, in hereditary forms of PD have supported a causative role for its aggregation in the disease 
process (Kalinderi, Bostantjopoulou and Fidani, 2016), although the molecular mechanisms by which this 
pathology occurs are still poorly understood. 
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Many of the biophysical properties of a-synuclein that have been established through in vitro studies have 
been shown to be valuable in interpreting in vivo models. In vitro aggregation assays using recombinant a-
synuclein have shown that its spontaneous aggregation is negligible at neutral pH, although when preformed 
seeds are added the reaction can proceed rapidly (Buell et al., 2014). At slightly acidic pH, secondary 
processes in which existing fibrils catalyse the formation of new ones on their surfaces start to dominate 
(Buell et al., 2014). Such conditions may be relevant in cellular compartments such as lysosomes and 
synaptic vesicles. Furthermore, the presence of small unilamellar vesicles (SUVs) in the aggregation assay 
dramatically increases primary nucleation as a-synuclein binds to the lipid bilayers, which initiates the 
aggregation process (Figure 1C,D) (Galvagnion et al., 2015, 2016). In agreement with the propensity of 
a-synuclein to interact with lipid membranes, genetic screens have systematically identified proteins 
involved in vesicle trafficking to be related to a-synuclein-mediated toxicity, as described in Section 4.2. 
These findings do not seem to arise simply as a result of the expression of a-synuclein in non-neuronal cell 
types such as yeast or C. elegans body wall muscle cells, as many of the proteins identified in the screens 
have been confirmed in neuronal models and in neurons from higher organisms (Cooper et al., 2006; Gitler 
et al., 2008; Hamamichi et al., 2008). 
 
Although the presence of mature Lewy body pathology does not appear to be essential for toxicity to be 
observed in the vast majority of in vivo models as discussed in Section 3.4, the process of protein 
aggregation is likely to play a causative role in synucleinopathies, given that the more aggregation prone 
a-synuclein variants such as A53T (Conway et al., 2000) or the C-terminal truncation fragment (Crowther 
et al., 1998) are typically associated with increased toxicity. Data on the A30P mutant are, however, more 
difficult to interpret, as its aggregation kinetics measured in vitro are very similar to those of the wild-type 
protein (Flagmeier et al., 2016), yet it does not readily form inclusions in yeast (Outeiro and Lindquist, 
2003) or in C. elegans body wall muscle cells (Perni et al., submitted), although A30P aggregates were 
demonstrated to form in fly (Feany and Bender, 2000) and rodent (Klein et al., 2002; Lo Bianco et al., 
2002; Lauwers et al., 2007; da Silveira et al., 2009) models. These differences may be related to the reduced 
affinity for lipid bilayers of this latter variant (Bodner et al., 2010). It will be interesting to study these 
mechanisms in more detail and also to carry out studies in vivo of the more recently identified familial PD 
mutants E46K, H50Q and G51D, which appear to be less aggregation prone in vitro (Flagmeier et al., 
2016), to shed more light on the aggregation process with respect to toxicity. 
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Oligomers have been suggested to play a key role in the toxicity of a-synuclein, although their molecular 
features in vivo have remained elusive. Stable a-synuclein oligomers can be generated in vitro and are toxic 
to neuronal cells in culture, causing increased levels of reactive oxygen species (Cremades et al., 2012; 
Chen et al., 2015). Detailed structural examination of stable toxic compared to non-toxic a-synuclein 
oligomers has revealed that toxicity is linked to strong binding to membrane surfaces and to insertion of a 
well-structured core into the lipid bilayer, whereas the more disordered species do not enter the bilayer and 
are not toxic (Fusco et al., 2017). This proposed mechanism of toxicity is interesting in the context of the 
interference with vesicle trafficking and lipid metabolism that was found in the in vivo models of a-
synuclein as described below in Section 4.2, highlighting the power of connecting the observations made 
in cellular and animal models with detailed biophysical characterisation in vitro to understand the 
mechanisms behind protein misfolding diseases. 
 
3. In vivo models of protein misfolding diseases 
 
A common way to create an in vivo model of a protein misfolding disease is through the transgenic 
expression of a human gene associated with the disease in a non-human organism. The gene may typically 
encode for the protein that misfolds and aggregates, or for a protein that regulates this process. These 
transgenic models are often based on mutant genes known from familial cases of the disease in order to 
obtain a strong phenotype with high penetrance. Overexpression is usually employed to obtain high levels 
of the disease-associated protein, which facilitates the detection of a response in the organism. 
 
Commonly used methods of probing the process of protein misfolding and aggregation in transgenic models 
include staining with amyloid-binding dyes or conformation-specific antibodies, ultrastructural 
examination by electron microscopy (EM), and biochemical assays based on the solubility, the size or the 
shape of the misfolded species (Table 1). In parallel, the phenotype of the model can be assessed both at 
the organismal and the cellular levels, with the goal of correlating the conformational state of the disease-
associated protein to neurotoxicity. In this section, we discuss this approach in the context of yeast, worm, 
fly and rodent models based on the transgenic expression of Ab, tau, or a-synuclein (Figure 3). 
 
3.1 Ab models 
 
Yeast models  
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Yeast, in particular Saccharomyces cerevisiae, is one of the simplest and most-studied eukaryotic organisms 
available for the study of cellular pathologies (Verduyckt et al., 2016; Tenreiro et al., 2017; Seynnaeve et 
al., 2018; Rencus-Lazar et al., 2019). This organism has a short generation time, and an arsenal of research 
tools is available for its study (Smith and Snyder, 2006). S. cerevisiae was the first eukaryote to have its 
complete genome sequenced (Goffeau et al., 1996), and we now know that at least 60% of the S. cerevisiae 
genes have significant homology, or share conserved domains, with human genes (Khurana and Lindquist, 
2010). However, since not all homologues have conserved functions, and not all human disease-related 
proteins have a yeast homologue, an often-used strategy to create a disease model is to express the human 
disease-related gene in yeast. 
 
Yeast lacks known homologues of APP and b- and g-secretases, yet transgenic variants of this organism 
have been successfully employed to investigate APP processing (Zhang et al., 1994, 1997; Lüthi et al., 
2003) and to screen for inhibitors of b-secretase (Middendorp et al., 2004) and Aβ-mediated toxicity 
(Bharadwaj et al., 2012; Amen and Kaganovich, 2016; Seynnaeve et al., 2018). It has proven challenging, 
however, to generate yeast models to observe the full Ab aggregation process and its associated toxicity 
(Verduyckt et al., 2016; Seynnaeve et al., 2018). Expression of Ab42 in fusion with green fluorescent 
protein (GFP-Ab42) in this organism was found to result in small punctate patches in newly transformed 
cells, which become larger as the cells age, and a modest reduction of about 5% in cellular growth was 
observed (Caine et al., 2007). Cells expressing an Ab42 fusion protein with the MRF domain of the yeast 
prion Sup35p have been reported as a model system for Ab42 oligomerization, where a decrease in activity 
of the reporter was shown to be associated with the formation of sodium dodecyl sulfate (SDS)-stable 
oligomers (Bagriantsev and Liebman, 2006). 
 
To model the generation of Ab in the secretory pathway, experiments have been carried out using the 
peptide fused to an ER-targeting sequence (Treusch et al., 2011). This model was shown to lead to the 
accumulation of Ab in the secretory pathway, accompanied by growth defects, which were more severe for 
Ab42 than for Ab40. Consistent with these observations, Ab42 was shown to form more oligomers than 
Ab40. These observations were confirmed in an independent study in which the expression of Ab42 with 
the ER-targeting sequence was furthermore shown to lead to impaired mitochondrial function and 
proteasomal activity (Chen and Petranovic, 2015). Further to these results, expression of an MFa-Ab42-
GFP fusion construct that also enters the secretory pathway and causes toxicity was found to be exacerbated 
for the familial, more aggregation-prone E22G Arctic mutant (D’Angelo et al., 2013), although the 
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aggregation state of the fusion proteins was not examined. An overview of the various yeast models used 
in the study of Ab aggregation can be found in Table 2. 
 
Worm models 
The nematode worm C. elegans has been used extensively to investigate the molecular processes underlying 
the cytotoxicity of Ab aggregation (Link, 2006; Alexander, Marfil and Li, 2014), and for the discovery of 
compounds capable of inhibiting such processes (Habchi et al., 2016; Perni et al., 2018). C. elegans has the 
advantage over yeast that it is multicellular, yet has a relatively simple body plan with 959 cells for the 
adult hermaphrodite, including a nervous system comprised of 302 neurons. The complete genome of C. 
elegans was sequenced in 1998 (The C. elegans sequencing consortium, 1998), and follow-up studies 
showed that 38% of the C. elegans genes have known human homologues (Shaye and Greenwald, 2011). 
The nematode typically lives up to 2-3 weeks in laboratory conditions, a convenient experimental timescale, 
and it has been shown to exhibit age-associated phenotypes, such as deterioration of muscle structure, as 
observed in higher organisms including humans (Herndon et al., 2002). 
 
Although C. elegans contains the APP homologue apl-1, this gene lacks a sequence region homologous to 
human Ab. Moreover, since C. elegans lacks the b-secretase activity required to process full-length APP, 
transgenic models have been largely based on the overexpression of the human Ab42 sequence (Table 3). 
In the first reported model, Ab42 was placed under control of the unc-54 promoter for expression in the 
body wall muscle cells (Link, 1995). For efficient expression, a signal sequence upstream of Ab was found 
to be required, and the peptide was shown to be properly processed, yet Ab deposits were found in the 
cytoplasm of the muscle cells rather than in the secretory system or in the extracellular space (Link et al., 
2001). However, co-immunoprecipitation has revealed that Ab interacts with the ER-homologue of the 
Hsp70 chaperone in this model, suggesting that it enters the secretory pathway, but is then rerouted to the 
cytoplasm for degradation (Fonte et al., 2002). Examination using amyloid-specific dyes and immuno-
electron microscopy (EM) has shown that a subset of the deposits is fibrillar, whereas a dimeric Ab 
construct forms deposits but without fibrillar structures (Fay et al., 1998; Link et al., 2001). From a set of 
mutants designed to interfere with b-strand formation, the L17P and M35C variants also fail to produce 
deposits that stain with amyloid-sensitive dye thioflavin S (ThS) (Fay et al., 1998). 
 
Subsequently, it was found that in the original model Ab is processed to residues 3-42 (McColl et al., 2009), 
a fragment that is a major component of human amyloid plaques with the N-terminal residue modified to a 
pyroglutamate (Harigaya et al., 2000). A model has therefore been created with two extra residues in 
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between the signal sequence and that of Ab, resulting in expression of the 1-42 peptide (McColl et al., 
2012). In both strains, amyloidogenic protein aggregation (Figure 3D, left panel) results in paralysis of the 
worms within several days of adulthood, yet the strain expressing Ab(1-42) is more temperature sensitive 
and shows increased paralysis at higher temperatures, perhaps reflecting differences in the aggregation 
behaviour of the two isoforms (McColl et al., 2012). 
 
A model in which Ab(3-42) is expressed in neurons features oligomeric species recognised by the NU-4 
antibody, and displays a phenotype with impaired chemotaxis (Wu et al., 2006) and defects in associative 
learning (Dosanjh et al., 2010). Interestingly, these worms are defective in sensing benzaldehyde, but not 
diacetyl, suggesting that the vulnerability of the associated sensory pathways towards Ab toxicity differs. 
In a more recent model expressing the corrected Ab(1-42) variant throughout the nervous system, the 
protein was found to accumulate in the insoluble fraction during ageing, whereas neuromuscular defects 
and behavioural abnormalities were observed earlier on (Fong et al., 2016). Expressing Ab specifically in 
glutamatergic neurons results in visible neurodegeneration of the glutamatergic neurons in the tail of the 
worm (Treusch et al., 2011). However, a model designed in our own laboratory that selectively expresses 
low levels of Ab42 in the two BAG sensory neurons, which are also glutamatergic, shows moderate 
behavioural defects in a CO2 sensing assay without overt signs of neurodegeneration, perhaps because these 
neurons are more resistant to toxic protein aggregation than others (Sinnige et al., 2019). Notably, in this 
model Ab42 appears to be localised mainly in the cell body (Figure 3D, right panel) and does not visibly 
form aggregates, supporting this notion. 
 
Fly models 
D. melanogaster, the fruit fly, is a common model organism for neurodegenerative diseases (Rincon-Limas, 
Jensen and Fernandez-Funez, 2012; Prüßing, Voigt and Schulz, 2013) (Table 4), whose main advantage 
over C. elegans is its more sophisticated nervous system. The central nervous system of the fly comprises 
glia as well as neurons, and contains specialised sub-structures such as a compound eye and mushroom 
bodies for olfactory learning and memory, both of which are often employed in disease models. Limitations 
for the modelling of neurodegenerative disorders, on the other hand, are the absence of an adaptive immune 
system, and a lack of blood vessels. 
 
Like C. elegans, Drosophila lacks a sequence region corresponding to human Ab in its APP homologue. A 
b-secretase homologue does exist (Carmine-Simmen et al., 2009), but has low levels of activity (Fossgreen 
et al., 1998; Greeve et al., 2004). g-secretase activity has also been demonstrated by expression in 
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Drosophila of a construct comprising the Ab region, the transmembrane region and the C-terminal segment 
of human APP, leading to generation of a 4 kDa Ab fragment that may correspond to either Ab40 or Ab42 
(Fossgreen et al., 1998). A transgenic model for Ab overproduction has been designed in which human 
APP is expressed together with human b-secretase in the eye, resulting in the generation of a 4 kDa Ab 
peptide and progressive degeneration of the retina and neuropil regions (Greeve et al., 2004). ThS-positive 
inclusions with a star-like appearance have been found in older flies, yet neurodegeneration precedes the 
formation of these amyloid deposits. Co-expression of human APP and b-secretase with Drosophila 
presenilin containing mutations corresponding to those in familial AD was found to reduce the onset of 
amyloid deposition remarkably, from 68 days to 37 days, and to cause more severe neurodegeneration 
(Greeve et al., 2004). 
 
Expression of human APP and b-secretase throughout the Drosophila nervous system was found to result 
in Ab deposition in the cortical layer, as shown by antibody staining, and memory defects in young flies, 
followed by extensive neurodegeneration in older flies (Sarantseva et al., 2009). Using a similar approach, 
a model has been generated that displays a more severe phenotype, including abnormal wing morphology 
at the time of eclosion and strong neuroanatomical changes, suggesting a developmental defect. In this 
model, punctate Ab deposits, which stain with the amyloid-binding dye X-34, are present in relatively 
young flies (Chakraborty et al., 2011). The reason for the discrepancy between these two models has been 
suggested to lie in the different caloric intake of the flies, which may affect g-secretase processing 
(Chakraborty et al., 2011). Raising the flies at lower temperature was found to result in a milder phenotype, 
with Ab deposits accumulating during ageing, accompanied by impaired climbing and memory functions 
and visible neurodegeneration (Mhatre et al., 2014). 
 
To avoid the complications associated with APP processing, another approach has been exploited in which 
Ab40 and Ab42 are directly expressed following the pre-proenkephalin signal peptide, which was shown 
to be cleaved correctly (Finelli et al., 2004). Flies expressing Ab42 have a rough eye phenotype and the 
peptide accumulates in the insoluble protein fraction, whereas flies expressing the less aggregation-prone 
Ab40 appear normal (Finelli et al., 2004). The lines that were created have varying expression levels of 
Ab42 in the eye, depending on the integration site of the construct and the number of copies. Aggregation 
and toxicity were found to be proportional to the expression levels, with low Ab42 levels showing small 
deposits and modest neurodegeneration, and higher levels resulting in larger deposits and more severe 
morphological defects (Finelli et al., 2004). 
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Expression of Ab42 throughout the nervous system leads to locomotory and other behavioural deficits in 
relatively young flies, in addition to a dramatically reduced lifespan (Finelli et al., 2004). Further 
characterisation of this model has revealed that Ab42 forms deposits in various regions of the brain, a subset 
in the region of the Kenyon cell bodies being ThS positive (Figure 3F) (Iijima et al., 2004). However, 
fibrils could not be identified by EM, suggesting that Ab42 forms diffuse, relatively unstructured deposits 
rather than mature amyloid plaques in this model. Similar experiments with Ab40 have shown that it 
accumulates in the same brain areas, but deposits are not visible. Whereas both Ab40 and Ab42 expression 
cause age-associated learning defects, only Ab42 results in locomotory defects and neurodegeneration at 
later ages. This observation suggests that visible protein aggregation is required in this model to observe 
neurodegeneration, but not neuronal dysfunction, which could perhaps be mediated by oligomers (Iijima et 
al., 2004). 
 
Using the signal peptide of the Drosophila necrotic gene, lines have been generated expressing Ab40 and 
Ab42, and also Ab42 with the Arctic mutation E22G in the Drosophila nervous system (Crowther et al., 
2005). All Ab variants were found initially to accumulate in intracellular deposits, which react with an 
antibody specific to oligomeric Ab (Crowther et al., 2005). In older flies, Ab42 shows extracellular deposits 
accompanied by vacuolar structures, which are exacerbated in the E22G mutant, whereas they do not occur 
in Ab40 flies. The extracellular deposits do not stain with Congo red, indicating that they do not consist of 
mature amyloid fibrils, but might resemble diffuse plaques as in the previously described fly model (Iijima 
et al., 2004). The Ab42 flies have a rough eye phenotype and locomotory defects, which occur before the 
appearance of the extracellular deposits, and the phenotype is exacerbated by the Arctic mutation. 
Furthermore, the Ab42 flies have a shorter lifespan than controls, whereas the survival of the Ab40 flies is 
indistinguishable from controls. The phenotype of the Ab42 flies can be partially restored by treatment with 
the amyloid-specific dye Congo red, suggesting that toxicity is directly caused by Ab42 aggregation. 
 
In a subsequent study, a panel of Ab42 mutants with different aggregation propensities has been expressed 
in the Drosophila nervous system. The computationally predicted aggregation rates were found to correlate 
strongly with lifespan and locomotory function, especially when the propensity to form protofibrillar 
(oligomeric) aggregates was considered (Luheshi et al., 2007). Similarly, whereas expression of Ab40 itself 
is relatively harmless to the flies, point mutations that increase the formation of prefibrillar Ab40 species 
in vitro result in a toxic phenotype when expressed in Drosophila (Brorsson et al., 2010). Furthermore, an 
engineered affibody has been shown to restore the phenotype of Ab42 flies, by binding to the monomer 
and targeting it for degradation (Luheshi et al., 2010). On the other hand, the KW1 antibody, which is 
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specific to Ab40 oligomers, induces aggregation into toxic protofibrillar species, shortening the lifespan of 
the flies (Wacker et al., 2014). Further evidence for the role of intermediate species in toxicity has been 
provided by the expression of tandem constructs of Ab40 and Ab42, in which two monomers are connected 
with a linker to increase the effective concentrations and aggregation rates. Expression of both tandem 
constructs leads to the formation of deposits in the fly brain, but only the tandem Ab42 flies show a dramatic 
reduction in lifespan relative to those expressing the monomeric peptide, an effect that is associated with 
an increase in SDS-soluble species (Speretta et al., 2012). 
 
Ab42, the E22G Arctic mutant, as well as a designed mutant with lower aggregation propensity have 
furthermore been expressed in the Drosophila nervous system using the pre-proenkephalin signal peptide 
(Iijima et al., 2008). In this study, the Ab variants were found to be localised intracellularly, residing in the 
endoplasmic reticulum (ER), Golgi and lysosomes, but in contrast to the model by Crowther and co-
workers, no oligomer-specific antibody staining was observed. None of the lines was found to show Congo 
red staining, demonstrating that mature fibrils are not noticeably formed either. The Arctic mutant shows 
an increased population of dimers and trimers by western blot, a larger number of ThS-positive deposits in 
the cell bodies accompanied by neuronal loss, a shortened lifespan and stronger locomotory defects than 
the model expressing wild-type Ab42. The designed mutant, however, forms more ThS-positive deposits 
in the neurites leading to neuropil loss, and has a longer lifespan, yet shows learning defects similar to the 
Arctic mutant. These discrepancies have been suggested to arise from a differential intracellular distribution 
of the variants, in addition to their different aggregation propensities, highlighting the importance of the 
biological environment in mediating cellular toxicity (Iijima et al., 2008). 
 
Further studies on flies expressing Ab variants in the giant fiber neurons have demonstrated that 
intracellular Ab, which accumulates in cell bodies and axons, leads to impairments in synaptic function, 
accompanied by reduced numbers of mitochondria and synaptic vesicles (Zhao et al., 2010). Again, the 
severity of the phenotype was found to be correlated with expression levels and to be stronger for the Arctic 
mutant. In addition, it has been shown that levels of the synaptic protein bruchpilot and presynaptic calcium 
channels decline with age in flies expressing the Arctic mutant, compared to controls (Huang et al., 2013). 
This Drosophila model expressing Ab in a subset of neurons has thus proved to be suitable to study 
perturbations at the single-neuron level, and has provided strong evidence for a connection between Ab 




One of first transgenic mouse models of AD shown to develop amyloid plaques resembling those in the 
human disease relied on the overexpression of the V717F mutant of human APP, which is associated with 
early-onset AD, driven by the platelet-derived growth factor b (PDGF-b) promoter (Games et al., 1995). 
These mice, referred to as PDAPP from the combination of PDGF-b and APP, show ThS-positive 
extracellular plaques accompanied by dystrophic neurites and reactive astrocytes. The plaques vary in 
morphology from round to diffuse. The pathology is age-related, with plaques first appearing between 6 
and 9 months of age, and increasing in number as the mice age further. This model displays synaptic loss 
correlated with increased plaque deposition in older mice (Dodart et al., 2000) as well as learning defects 
(Chen et al., 2000), but without overt neuronal loss (Irizarry et al., 1997). 
 
A wide variety of models based on mutant APP overexpression has been subsequently generated, which 
similarly display amyloid plaques and are associated with synaptic dysfunction and gliosis (reviewed in 
(Elder, Gama Sosa and De Gasperi, 2010; Hall and Roberson, 2012; Drummond and Wisniewski, 2017); 
see www.alzforum.org for a full list of available rodent models and Table 5 for those discussed here). These 
models differ from one another in various ways including the ratio of Ab40 to Ab42, the morphology of 
the plaques, the age at which they appear and the brain regions that are affected. A widely used model is 
the Tg2576 mouse, in which human APP is overexpressed with the Swedish double mutation 
K670N/M671L using the prion protein (PrP) promoter that drives strong expression in neurons (Hsiao et 
al., 1996). In this model, dense ThS-positive deposits are found in older mice (11-13 months), a subset of 
which display Congo red birefringence. Dystrophic neurites have also been found in this case, as well as 
reactive astrocytes and microglia. At the age where plaques are apparent, the mice show behavioural 
impairment in the Morris water maze test. However, there is no direct correlation between the quantity of 
plaques and cognitive defects, as the behavioural phenotype remains stable between 6 and 14 months, while 
the plaque load continues to increase. Rather, the levels of a 56 kDa soluble Ab species, referred to as 
Ab*56, identified in extracts from Tg2576 mice by SDS PAGE and size exclusion chromatography (SEC) 
(Table 1) correlate with memory impairment (Lesné et al., 2006). Furthermore, this species affects long-
term memory when purified and infused into young rats, supporting the hypothesis that Ab oligomers are 
responsible for neurotoxicity in AD. 
 
A complication of APP-based transgenic mouse models is that its processing gives rise to several variants 
of the Ab peptide, as well as other intracellular and extracellular fragments of APP (Figure 2A), which 
may all contribute to the observed phenotype. To address specifically the role of Ab accumulation, a 
different approach has been taken in expressing constructs comprising the BRI protein fused to either Ab40 
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or to Ab42, which are released by the furin cleavage site directly preceding the Ab sequence (McGowan et 
al., 2005). Expression of the Ab40 construct leads to high levels of free peptide, which however remains 
soluble, so that no amyloid plaques are observed. In contrast, BRI-Ab42 mice show amyloid pathology 
starting at 3 months of age, including the presence of diffuse and compact ThS-positive plaques, as well as 
deposits in blood vessels in the brain, termed cerebral amyloid angiopathy (CAA). However, although 
dystrophic neurites and reactive astrogliosis have been observed surrounding the plaques, this study 
reported that the mice have no behavioural abnormalities, suggesting that Ab42 deposition by itself is not 
sufficient to trigger neurotoxicity, at least up to the age investigated (McGowan et al., 2005). It is interesting 
to compare these findings to those from the Drosophila and C. elegans models discussed above, where Ab 
fusions do lead to behavioural phenotypes. These observations can perhaps be attributed to toxicity arising 
from intracellular rather than extracellular Ab in these worm and fly models. Intracellular Ab may also be 
present in APP-based mouse models (LaFerla, Green and Oddo, 2007), but not in those developed using 
the BRI fusion approach. 
 
Mutations in the presenilin genes PSEN1 and PSEN2 associated with early onset forms of AD have been 
employed to increase the levels of the more aggregation-prone Ab42 in mouse models. Expression of 
familial mutant, but not wild-type, PSEN1 has been shown to increase specifically the levels of Ab42 over 
Ab40 in mice (Borchelt et al., 1996; Duff et al., 1996; Citron et al., 1997), and crossing these lines with 
APP mutant mice has led to accelerated Ab deposition (Borchelt et al., 1997; Holcomb et al., 1998). Several 
PSAPP mouse models based on different combinations of APP and PSEN1/2 mutants exist, and all show 
similar pathologies to that of the APP transgenic mice, but at an earlier age and accompanied by a stronger 
behavioural phenotype. They also suffer from greater neuronal loss, although not at levels comparable to 
the widespread degeneration in human AD (McGowan, Eriksen and Hutton, 2006; Elder, Gama Sosa and 
De Gasperi, 2010; Hall and Roberson, 2012). For example, the PS2APP mouse model, a cross of the APP 
K670N/M671L mutant and PSEN2 with the N141I mutation, displays congophilic amyloid plaques at 9 
months of age, which are surrounded by dystrophic neurites and activated microglia and astrocytes 
(Richards et al., 2003). However, deficiencies in synaptic plasticity and behavioural tests such as the Morris 
water maze are relatively mild (Richards et al., 2003). 
 
In the APPSLPS1KI mouse model, which expresses APP with V717I and K670N/M671L mutations, and 
PSEN1 with M233T and L235P mutations, large numbers of plaques are already apparent at 6 months of 
age, and about 50% neuronal loss in the CA1/2 layer of the hippocampus has been observed at 10 months 
of age (Casas et al., 2004). The loss of neurons appears to correlate better with the presence of intracellular 
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Ab aggregates that can be stained with ThS than with extracellular plaques, which is interesting given the 
evidence for the presence of intracellular Ab in human AD (LaFerla, Green and Oddo, 2007). Coinciding 
with this pathology, the mice become increasingly impaired in working memory and motor tasks from 6 
months of age (Wirths et al., 2008). Apart from the fact that this model produces Ab42 as the dominant Ab 
species, another interesting feature in relation to human AD is the progressive N-terminal truncation and 
modification of Ab42 into species that have been detected in patient material (Casas et al., 2004). 
 
A model with very extensive amyloid deposition has been created using the L166P mutant form of PSEN1, 
which has led to a disease onset as young as 24 years of age in humans, crossed with a mouse strain 
expressing APP K670N/M671L (Radde et al., 2006). In the resulting model, congophilic amyloid plaques 
appear in the neocortex at 6 weeks, whereas deposits in different regions of the hippocampus occur between 
2 and 5 months. As in the other mouse models, the plaques are surrounded by dystrophic neurites and glia, 
but cognitive impairment is only evident at 8 months (Radde et al., 2006). 
  
The approach of combining APP and PSEN mutants has been further extended through the generation of a 
mouse strain with a total of five familial AD mutations, the 5xFAD mouse, which has become one of the 
most frequently used models in AD research (Oakley et al., 2006). Constructs of APP with K670N/M671L, 
I716V and V717I mutations, and PSEN1 with M146L/L286V, were co-injected to create this model, 
resulting in rapid accumulation of Ab42 and ThS-positive plaques from 2 months of age. The plaques are 
smaller but more numerous than in the Tg2576 mouse, consistent with an increase in nucleation events due 
to the higher concentration of Ab42. In this model, intracellular Ab aggregation also appears to play a role, 
as indicated by small ThS-positive puncta in pyramidal neurons. It has been speculated that extracellular 
plaques could arise from these aggregates upon cell death, as indeed degenerating neurons with intracellular 
deposits are sometimes found in the vicinity of plaques. These regions of co-localisation are correlated with 
synaptic degeneration and significant loss of neurons. At the behavioural level, there is no phenotype at 2 
months in these mice, but at 4-5 months, memory defects are apparent in the Y-maze test (Oakley et al., 
2006). 
 
Mouse models based on the overexpression of human genes produce artificially high protein levels, 
including other APP fragments in addition to Ab, including those coming from the a-secretase pathway, 
some of which may also be amyloidogenic [Vandersteen, Annelies, et al. "A comparative analysis of the 
aggregation behavior of amyloid‐β peptide variants." FEBS letters 586.23 (2012): 4088-4093], and altering 
in complex ways the protein homeostasis system [Saito, Takashi, et al. "Calpain activation in Alzheimer's 
model mice is an artifact of APP and presenilin overexpression." Journal of Neuroscience 36.38 (2016): 
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9933-9936], altogether complicating the interpretation of the phenotype. Second generation mouse models 
remedy some of these issues by making use of knock-in strategies to produce human Ab in the context of 
endogenous mouse APP (Sasaguri et al., 2017). For example, the Ab sequence of mouse APP was 
humanised, and Swedish (K670M/M671L) and Iberian (I716F) mutations were introduced in order to 
generate high levels of preferentially Ab42 (Saito et al., 2014). The resulting APPNL-F mice display 
progressive Ab pathology and inflammation, accompanied by memory impairment in the Y-maze test. 
Adding the Arctic mutation E693G has resulted in the APPNL-G-F/NL-G-F model that displays earlier Ab 
deposition and a stronger inflammatory response. 
 
Another strategy to avoid overexpression consists in triggering an amyloid cascade response by 
intracerebral infusion of Ab seed aggregates produced either in vitro or derived from cell systems, other 
animal models, or AD patients (Jucker and Walker, 2018). These non-transgenic mouse models are 
particularly useful in the study of the mechanisms of propagation of the aggregates across cells and brain 
tissues, but the infusion process tends to generate inflammatory reactions that complicate the interpretation 
of the results. 
 
Given that rats are evolutionarily more closely related to humans than mice, and display more complex 
patterns of behaviour, rat models have certain advantages for recapitulating and testing the pathogenic 
mechanisms behind AD. Although early rat models transgenic for APP did not display amyloid plaques, 
probably due to insufficient levels of expression (reviewed in (Carmo and Cuello, 2013)), the McGill-R-
Thy1-APP model has been successful in generating many aspects of AD pathology with just a single 
transgene of APP combining Swedish (K670N/M671L) and Indiana (V717F) mutations (Leon et al., 2010). 
These rats accumulate intracellular Ab from just one week after birth, and the first amyloid deposits show 
at 6 months in a particular brain region, the subiculum. Investigations in older animals have specifically 
identified degenerating glutamatergic and cholinergic neurons surrounding compact, ThS-positive plaques, 
showing the vulnerability of these types of neurons. Furthermore, the levels of soluble trimeric Ab species 
are greatly elevated in homozygous rats, and were found to correlate with learning and memory deficits at 
3 months of age (Leon et al., 2010). This observation points towards toxicity of soluble Ab species, rather 
than mature amyloid plaques. This model thus recapitulates many features of human AD, although a 
subsequent study has shown that neuronal loss is in fact very limited, being largely restricted to the 
subiculum at 18 months of age (Ingrid et al., 2015). 
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Another useful rat model, TgF344-AD, has been developed by expressing K670N/M671L mutant APP and 
PSEN1 with a deletion of exon 9 (R. M. Cohen et al., 2013). At 16 months of age, the rats display 
widespread deposition of ThS-positive amyloid plaques in the cingulate cortex and hippocampus, as well 
as the striatum and cerebellum, all of which are regions affected by amyloid deposition in AD patients. The 
model also features intraneuronal accumulation of Ab42, and soluble oligomeric Ab species have been 
found which correlate with significant neuronal loss; in addition the model displays inflammation and 
phagocytosis of neuronal debris. At the behavioural level, the rats show defects in various assays, and these 
progress with age following the development of the observed pathology. In contrast to most APP/PSEN 
based mouse models, this rat model displays tau pathology consisting of Gallyas silver stained tangles both 
in vicinity of the amyloid plaques, and also in regions devoid of plaques, as observed in human AD (Braak 
and Braak, 1991). The presence of tau tangles is critical to study the interplay between Ab and tau 
pathology, which is still poorly understood, as outlined in the next sections. 
 
 
3.2 Tau models 
 
Yeast models 
Yeast models have been employed to compare the in vivo aggregation propensities of various tau isoforms 
and disease-associated mutations, as well as the role of specific phosphorylation sites (Table 2). Upon 
expression of the human tau isoforms 2N3R and 2N4R in yeast, a small fraction of both protein constructs 
accumulates in the sarkosyl-insoluble aggregate fraction, with the 2N4R isoform being more extensively 
phosphorylated than the 2N3R isoform (Vandebroek et al., 2005). Comparison of a set of six familial point 
mutants in the 2N4R isoform showed that all become hyperphosphorylated, and accumulate more strongly 
in the sarkosyl-insoluble fraction than the wild-type protein (Vanhelmont et al., 2010). Purified 
hyperphosphorylated, soluble wild-type tau quickly forms structured filaments in vitro, and is able to seed 
tau isolated from transgenic yeast cells (Vandebroek et al., 2005). The P301L tau variant found in FTDP-
17 patients, purified from yeast, has been shown to aggregate in vitro when presented with a microtubule 
surface as a substrate, in contrast to wild-type tau-4R (Vandebroek et al., 2006). Although yeast models 
have thus confirmed key aspects of tau phosphorylation and aggregation, no toxicity has been observed in 
any of the reported expression systems as judged from the growth rates of the cells (Vandebroek et al., 




The first C. elegans models of tauopathy have been based on the overexpression of a construct comprising 
human tau 1N4R in nerve cells (Kraemer et al., 2003). In addition to that expressing the wild-type protein, 
lines expressing the mutants P301L and V337M, which are associated with Frontotemporal dementia and 
parkinsonism linked to chromosome 17 (FTDP-17),  have been generated, all resulting in an uncoordinated 
phenotype with reduced thrashing rates and shortened lifespan. Tau becomes phosphorylated at the majority 
of known sites in these models, and it accumulates in the detergent-soluble fraction as the worms age, as 
well as in the detergent-insoluble fraction in the case of the mutant lines. In addition to presynaptic defects 
in cholinergic transmission, degeneration of GABAergic axons has been observed. However, tau was found 
to be diffusely localised in the axons, and only the V337M variant showed clear deposits in electron 
micrographs. This mutant line contains the highest level of insoluble tau, and displays the strongest 
phenotype, but the results obtained on wild-type and P301L tau suggest that the formation of deposits is 
not required for neurodegeneration (Kraemer et al., 2003). 
 
A study in which the 3R and 4R isoforms of wild-type tau, and the 4R isoforms of P301L and R406W were 
expressed specifically in the six mechanosensory neurons of C. elegans has largely corroborated these 
findings (Miyasaka et al., 2005). The touch response is only mildly affected in worms expressing wild-type 
tau, but declines strongly with age in the mutant strains, both of which show corresponding signs of 
neurodegeneration. Ultrastructural examination by EM has shown accumulation of tau in the cell bodies 
and neuronal processes with concomitant loss of microtubules, yet no evidence for fibrillar aggregates was 
found. 
 
Expression of different tau variants with increased or decreased aggregation propensities has, however, 
highlighted the relevance of toxic protein aggregates in the C. elegans models. Co-expression of  V337M 
tau with a short aggregation-prone tau fragment, F3DK280, leads to the formation of ThS-positive 
inclusions, and increased accumulation of full-length tau in the detergent-soluble and detergent-insoluble 
fractions during ageing compared to the strain expressing V337M tau alone (Fatouros et al., 2012). 
Concomitantly, the locomotory phenotype is more severe, the neurons display more morphological 
abnormalities, and the transport of mitochondria is perturbed. The introduction of mutations predicted to 
prevent the formation of b-strands in the F3DK280 fragment has the opposite effect, and in addition 
compounds known to inhibit tau aggregation have been shown to reduce the accumulation of insoluble tau 
and partially restore the locomotory phenotype of the strain expressing the aggregation-prone fragment 




The first observation of tau toxicity in flies was serendipitous, when a reporter construct consisting of 
Drosophila tau tagged with GFP was expressed in sensory neurons with the aim to study axonal 
development. Morphological defects were observed, providing the first demonstration of tau toxicity in the 
fly, and similar results were obtained upon expression of human tau (Williams, Tyrer and Shepherd, 2000). 
Since then, Drosophila has been used extensively to study tau aggregation and toxicity, as well as the effects 
of phosphorylation by different kinases (see (Sun and Chen, 2014) for a more complete overview, and 
Table 4 for the models here discussed). As in yeast and C. elegans, the effects of FTDP-17 mutations have 
also been examined, for example in models expressing human wild-type and R406W tau forms throughout 
the nervous system (Wittmann et al., 2001). Although both of these strains display a reduction in lifespan, 
the phenotype is stronger for the R406W mutant, and severe neurodegeneration is evident from vacuolar 
structures in the cortex. Both the wild-type and R406W tau forms are recognised by antibodies specific to 
pathogenic phosphorylation and misfolded conformations of tau, but evidence for fibrillar structures has 
not been found in investigations by EM. 
 
Co-expression of the Drosophila homologue of the kinase GSK-3β with full-length tau in the fly eye does 
result in the characteristic flame-shaped aggregates resembling those found in human tauopathies (Jackson 
et al., 2002). The antibody AT100, which is specific for phosphorylated tau in tangles, recognises tau only 
when co-expressed with GSK-3β in the fly. Co-expression of the kinase results in fibrillar aggregates with 
the dimensions of human paired helical filaments (PHFs) and straight filaments (SFs) as seen by EM, and 
exacerbates neurodegeneration compared to the expression of tau alone (Jackson et al., 2002). In agreement 
with the toxic effects of phosphorylation by GSK-3β, inhibition of the kinase restores the locomotory 
phenotype in a model expressing human wild-type tau 0N3R in motor neurons (Mudher et al., 2004). 
Another kinase, PAR-1, has been shown to phosphorylate tau upstream of GSK-3β, and its overexpression 
exacerbates the rough eye phenotype of the R406W model, but in the absence of visible tau aggregates 
(Nishimura, Yang and Lu, 2004). 
 
In certain tauopathies, fibrillary tangles occur in glia in addition to neurons (Lee, Goedert and Trojanowski, 
2001). A Drosophila model in which human 0N4R tau is expressed specifically in adult glia shows a 
reduction in lifespan and the presence of apoptotic signals in glia and, by non-cell autonomous mechanisms, 
in cholinergic neurons (Colodner and Feany, 2010). In aged flies, tau is found in sarkosyl-insoluble 
fractions, which contain straight fibrils as shown by EM studies. Immunohistochemistry has confirmed that 
the glia contain inclusions consisting of phosphorylated tau, which are furthermore positive for ThS and 
Bielschowsky silver staining, and contain fibrillar structures in EM. Expression of tau in both glia and 
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neurons leads to increased toxicity compared to that in neurons alone, as measured by the number of 
apoptotic cells, indicating the importance of glial tau in these neurodegenerative disorders. 
 
In a recent study, a comparison of a panel of Drosophila models expressing wild-type tau and five FTDP-
17-linked mutations at similar expression levels has further strengthened the correlation between tau 
phosphorylation and neurotoxicity (Bardai et al., 2018). Mutants that display the strongest aggregation, 
indicated by the number of inclusions in vivo and ThS fluorescence of the corresponding recombinant 
proteins in vitro, show the least caspase activation and induction of stress signalling, demonstrating that 
mature aggregates do not cause significant toxicity. The mutants generating the highest toxicity, on the 
other hand, have the highest phosphorylation levels and show increased F-actin accumulation, suggesting 
a correlation between actin stabilisation and toxicity (Bardai et al., 2018). 
 
Rodent models 
As in the case of APP-based mouse models, initial rodent models overexpressing human wild-type tau 
constructs have not displayed clear behavioural phenotypes, nor produced significant numbers of tau 
tangles, which is why most models have been generated using tau with mutations found in FTDP-17 
(reviewed in (Hutton et al., 2001; Lee, Kenyon and Trojanowski, 2005)). An overview of about 30 current 
transgenic mouse models of tau is available on www.alzforum.org; we highlight here those that are 
commonly used, or that have led to particularly interesting insights (Table 5). 
 
One of the few successful models based on wild-type tau is the htau model, a cross of a strain expressing 
human tau, including all regulatory regions and leading to all splicing variants, with a knock-out strain for 
endogenous mouse tau (Andorfer et al., 2003). Expression of the human construct by itself does not lead to 
clear tau pathology (Duff et al., 2000), suggesting that the interplay between mouse (which only occurs as 
4R) and human isoforms is important. In the htau model, tau was observed to be correctly localised in the 
axons in 6-week-old animals, but tau staining was found to shift towards the cell bodies as the animals age, 
accompanied by increased phosphorylation at particular sites. Beyond 9 months, tau aggregation was 
inferred from immunohistochemistry and immuno-EM, and the sarkosyl-insoluble fraction was found to 
contain PHFs with similar dimensions as the ones found in AD brains (Andorfer et al., 2003). The mice 
suffer significant neuronal loss at old age, between 8 and 18 months, but the majority of dying neurons does 
not appear to contain fibrillar aggregates (Andorfer et al., 2005). However, memory impairments and 
synaptic defects occur at 12 months, but not at 4 months, indicating that tau pathology does need to develop 
to a certain stage to cause damage (Polydoro et al., 2009). 
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A more recent model based on wild-type tau, Tau4RTg2652, has been generated to overexpress high levels 
of 1N4R wild-type tau, driven by the Thy1.2 promoter, resulting in approximately 12-fold overexpression 
relative to endogenous mouse tau (Wheeler et al., 2015). In this model, misfolded and phosphorylated tau 
is detectable by various antibodies in the forebrain, amygdala, hippocampus and brainstem even at 3 
months, but tangles are not observed by ThS and Gallyas staining even at 24 months of age. The levels of 
oligomeric tau as recognised by the TOC1 antibody are relatively low, but abnormal axon morphologies 
and dystrophic neurites have been nevertheless identified throughout the brain. The mice show a slight 
motor phenotype, but the most obvious behavioural phenotype is an impairment in spatial memory as 
assessed in the Barnes maze test. Altogether, these data suggest that pre-tangle tau, consisting of altered 
conformations and phosphorylation states, but not oligomers or fibrils, could be sufficient to drive neuronal 
dysfunction. Both the tau pathology and the behavioural phenotype remain stable from 3 months onwards, 
which may make this model suitable for rapid studies of the early stages of sporadic tauopathies, including 
AD. 
 
Most other existing tau models are based on tau mutations linked to FTDP-17, which are not directly related 
to AD, but provide strong phenotypes, which are useful for fundamental studies of tau pathology, as well 
as for preclinical trials targeted at halting tau toxicity. The JNPL3 mouse, overexpressing tau 0N4R with 
the P301L mutation from the PrP promoter, shows impaired motor function and abundant tau tangles in 
several regions of the brain as well as the spinal cord; the latter are, however, typically not associated with 
AD (Lewis et al., 2000). The tau accumulations are recognised by a range of conformational and phospho-
specific antibodies, and are positive for Congo red, ThS and other staining agents such as Gallyas silver. 
Different morphologies have been found, including the flame-shaped tangles characteristic of AD, but also 
aggregates resembling Pick bodies and small, dense inclusions similar to those found in FTDP-17. EM 
studies have confirmed the presence of fibrils, and sarkosyl-insoluble protein has been found in extracts of 
brain and spinal cord from aged JNPL3 mice, but not from control lines expressing wild-type human tau. 
 
In another mouse model, known as pR5, the P301L mutant is expressed in the context of the longest tau 
isoform 2N4R under the control of the Thy1.2 promoter (J. Götz et al., 2001). In this model, tau also 
accumulates in various brain regions, and forms tangles stained by ThS and Gallyas silver in e.g. the spinal 
cord and layers 5 and 6 of the cortex. Reactive astrocytes and apoptotic neurons have been found in the 
same regions. Other neurons, including pyramidal cells in the hippocampus, show granular tau 
accumulation that is recognised by a subset of phospho- and conformation-specific antibodies. The 
sarkosyl-insoluble fraction of brain extracts contains fibrils as seen by EM, but they are shorter and 
narrower than fibrils obtained from AD patient material. This is in line with the observation that P301L 
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fibrils from FTDP-17 patients have a different morphology from that of V337M FTDP-17 fibrils or wild-
type AD fibrils (Spillantini, R A Crowther, et al., 1998), suggesting that the point mutations can 
significantly affect fibril structure. Furthermore, the strong overexpression in mouse models may give rise 
to shorter fibrils than those observed in AD, because the likelihood of primary nucleation is higher. 
 
The rTg4510 model has also been designed to express P301L tau (0N4R), in this case using an elegant 
expression system that can be inhibited with doxycycline (Ramsden et al., 2005; SantaCruz et al., 2005). 
The Ca2+/calmodulin kinase II (CaMKII) promoter has been used to drive expression specifically in the 
forebrain, where the first tau tangles appear at 2.5 months of age, leading up to extensive tau pathology and 
increasing atrophy in the cortex and hippocampus from 5 months onwards (Ramsden et al., 2005). 
Misfolded tau conformations and phosphorylation also develop with age, as indicated using various 
antibodies, and the main tau species shifts from the soluble 55 kDa form at 2.5 months to the sarkosyl-
insoluble, extensively phosphorylated 64 kDa-species at 8.5 months. At the ultrastructural level, straight 
filaments have been observed in EM on fixed tissue samples from 10-month-old animals, which 
occasionally adopt a typical herring bone pattern which has also been observed in deposits in Pick’s disease. 
At the behavioural level, spatial memory in the Morris water maze test is impaired from 4 months of age, 
and locomotory deficits have been observed in 10-month old mice (Ramsden et al., 2005).  
 
The possibility of lowering tau expression in this model has led to interesting insights into the relationship 
between tau pathology and toxicity (SantaCruz et al., 2005). Suppressing tau expression at 2.5 months 
causes the pathology to be halted. In contrast, when doxycycline treatment is given at 4 months or later, tau 
phosphorylation and accumulation in the insoluble fraction proceed, and numbers of tau tangles grow 
similarly as in untreated animals. Given the significant reduction in tau mRNA, this suggests that the soluble 
species that were already present can develop into pathological tau. However, brain atrophy and memory 
defects were found to be largely restored if the doxycycline treatment was sufficiently long, demonstrating 
that the presence of tau tangles is not directly correlated with the disruption of cognitive function (SantaCruz 
et al., 2005). 
 
A model expressing  tau 1N4R with the P301S mutation, PS19, shows a strong motor phenotype which 
presents difficulties for behavioural studies, yet it has been a useful model because of its robust tau 
pathology and evident neurodegeneration (Yoshiyama et al., 2007). Phosphorylated tau has been shown to 
accumulate rapidly, and increased levels of insoluble tau have been observed during ageing. At 6 months 
of age, flame-shaped tau tangles and globular aggregates, as well as thread-like structures, can be visualised 
in the hippocampus, amygdala and spinal cord by Gallyas silver staining, and by staining with ThS and 
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Congo red. Activated microglia and astrocytes, as well as neuronal inflammatory markers, develop from 3 
months onward. Tau pathology and inflammation precede large scale neurodegeneration, which is observed 
from 9 months onwards in the hippocampus and other brain regions. However, hippocampal synapses are 
already lost by 3 months of age, preceding the appearance of tau tangles. As such, the results obtained from 
this model add to the notion that neurodegeneration is initiated before mature protein aggregates are formed. 
 
The ∆K280 mutation, which is known from a FTDP-17 case, is directly correlated with the aggregation 
propensity of tau, being located in a segment of the protein that forms a b-strand in the fibril structure. 
Mouse models based on this pro-aggregation mutant have been generated in parallel with an anti-
aggregation mutant consisting of ∆K280 combined with two proline mutations (I277P and I308P), which 
strongly inhibit b-strand formation (Eckermann et al., 2007; Mocanu et al., 2008). These mutants have been 
expressed in the context of full-length human tau 2N4R (Eckermann et al., 2007), and in a short construct 
comprising only the repeat domain of tau (Mocanu et al., 2008) in two respective studies, leading to very 
similar results. The pro-aggregation mutant adopts a misfolded conformation that is recognised by the MC1 
antibody, becomes phosphorylated at several sites and is partially found in the sarkosyl-insoluble fraction, 
whereas the anti-aggregation mutant does not display these features. Furthermore, the pro-aggregation 
mutant has been shown to induce co-aggregation of endogenous mouse tau, which co-localises with the 
exogenous human tau in the same filaments extracted from the mouse brain. In both studies, quantification 
from electron micrographs has shown that the pro-aggregation mutant causes more synaptic loss than the 
anti-aggregation mutant. The strong correlation between in vitro and in vivo aggregation propensities is 
furthermore underscored by the fact that the truncated construct leads to Gallyas-positive tau tangles much 
earlier than full-length tau, in line with a protective effect of the flanking regions on tau aggregation 
observed in vitro. These models also make use of the regulatable expression system, and switching off tau 
expression has been shown largely to reverse tau pathology (Eckermann et al., 2007; Mocanu et al., 2008), 
in contrast to the earlier study which reported that tau tangles continue to develop after reducing transgene 
expression, although memory function recovered (SantaCruz et al., 2005).  However, phosphorylation and 
aggregation of endogenous mouse tau persist in the pro-aggregation model, possibly seeded by the 
pathological human tau expressed prior to switching off the transgene (Mocanu et al., 2008). 
 
More recently, mouse models have been generated expressing tau with the A152T mutation, which has 
been found to increase the risk of FTD as well as AD. In one model, the mutation has been introduced in 
the context of full length tau 2N4R (Decker et al., 2016; Sydow et al., 2016), whereas another model that 
was simultaneously reported is based on the expression of tau 1N4R (Maeda et al., 2016). Both models 
display reactive microglia and astrocytes and neuronal hyperexcitability, with deficits in behavioural assays 
 31 
and neuronal loss occurring at later age. The model expressing A152T tau 2N4R was shown to develop 
ThS and Gallyas silver positive tau tangles starting from 3 months of age (Sydow et al., 2016), but in the 
model expressing the 1N4R isoform, the misfolded tau was found to remain largely soluble (Maeda et al., 
2016). Thus, soluble A152T tau oligomers may be responsible for the overlapping phenotypes of these two 
models. 
 
Rat transgenic models have been used less extensively than mouse to study human tauopathies. A rat model 
expressing full-length tau with the P301L mutation displays tau phosphorylation and accumulation in the 
sarkosyl-insoluble fraction, but no tangles, nor behavioural abnormalities (Korhonen et al., 2011). Models 
based on truncated 4R and 3R isoforms (residues 151-391), which are thought to play a role in AD, do 
display full tau pathology including the presence of phosphorylated, misfolded and sarkosyl-insoluble tau, 
and ThS and Congo red positive tangles, but without overt neuronal loss (Zilka et al., 2006; Koson et al., 
2008; Filipcik et al., 2012).  
 
 
3.3 Models combining Ab and tau 
 
Worm models 
The link between Ab and tau pathologies in AD has remained incompletely understood, in part because 
animal models have not been particularly successful in recapitulating both features of the disease. Crossing 
C. elegans strains expressing Ab42 and an aggregation-prone tau mutant in neurons was shown to lead to 
an exacerbation of the toxic phenotype in terms of lifespan, viability of offspring, chemotaxis and other 
behavioural assays (Wang et al., 2018). Conversely, crossing an anti-aggregation tau variant and an Ab42 
strain has not led to a significantly different phenotype compared to Ab42 alone. The total aggregation load 
as seen from Congo red staining was found to be much increased in the double transgenic line with the pro-
aggregation tau mutant, and signs of neurodegeneration and neuronal loss were observed, but a mechanistic 
link between Ab42 and tau toxicity has not been revealed from these studies. 
 
Fly models 
Co-expression of Ab42 has been shown to exacerbate the phenotype of wild-type human tau transgenic 
flies, manifesting in disrupted axonal transport, abnormal axonal morphology, impaired motor function, 
and shortened lifespan (Folwell et al., 2010). This effect has been suggested to be mediated by increased 
tau phosphorylation in the presence of Ab42, but the responsible kinases have so far not been identified. In 
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an inducible fly model expressing Ab42 with the Arctic mutation (E22G), the Drosophila kinase GSK-3β 
is activated, and Ab42-mediated toxicity is reduced when endogenous fly tau is removed (Sofola et al., 
2010). However, differences in the phosphorylation of Drosophila tau in the presence or absence of Arctic 
Ab42 are below detection limits. Thus, the link between Ab42 and tau phosphorylation remains unclear 
from the Drosophila studies. 
 
Rodent models 
APP/PSEN-based rodent models have largely failed to induce significant tau pathology, although tau 
knock-out models have demonstrated that the presence of tau is required for Ab-related toxicity to occur 
fully (Roberson et al., 2007; Leroy et al., 2012). To induce both Ab and tau pathology, however, it has been 
necessary to develop double or triple transgenic models overproducing combinations of human APP, 
PSEN1/2 and tau, often with mutations that do not occur simultaneously in AD patients. Nevertheless, these 
models have proved to be useful for understanding the interactions between Ab and tau pathology in AD. 
 
The first transgenic mouse model combining APP with tau has been the TAPP mouse, resulting from a 
cross of Tg2576, which expresses APP containing the Swedish mutation (K670N/M671L) with the JNPL3 
mouse, which expresses the P301L tau variant (Lewis et al., 2001). The number of tau tangles is highly 
increased in the TAPP mouse compared to the original JNPL3 mouse, and tangles are found in brain regions 
that are unaffected in the JNPL3 model, including the hippocampus, amygdala and entorhinal cortex. Other 
regions that are affected by tau pathology in the JNPL3 mouse, such as the hindbrain and spinal cord, do 
not show an increase. Ab deposition is, however, not changed compared to the Tg2576 model, in line with 
the amyloid cascade hypothesis, according to which Ab aggregation occurs upstream of tau pathology 
(Selkoe and Hardy, 2016). Despite the clear link, tau tangles are not identified in close vicinity of amyloid 
plaques, indicating that other mechanisms, perhaps mediated by intracellular Ab, may play a role. These 
results have been confirmed by an independent study in which Ab42 fibrils were injected in the pR5 mouse 
model which also expresses tau P301L, resulting in a 5-fold increase in tau tangles (J Götz et al., 2001). In 
this experiment, the main increase in tau tangles was found in neurons in the amygdala, which are distant 
but projecting towards the injection site, raising the possibility that retrograde transport of Ab42 can 
promote tau tangle formation. 
 
A triple transgenic mouse model, the 3xTg-AD mouse, has been created by co-injecting constructs of the 
Swedish APP variant (K670N/M671L) and the P301L tau variant into embryos carrying the M146V PSEN1 
variant (Oddo et al., 2003). This model has been used extensively in AD research because the temporal and 
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spatial appearance of amyloid plaques and tau tangles resembles that observed in the human disease. 
Antibody staining for Ab is first observed intracellularly at 3-4 months of age, mostly in the neocortex and 
subsequently in the hippocampus. Plaques develop progressively in the same regions between 6 and 12 
months. Tau pathology is initiated later and follows a different spatial pattern, first accumulating in 
pyramidal neurons in the hippocampus, followed by cortical regions. Aggregated tau can be recognised by 
conformation-specific and phospho-specific antibodies, as well as Gallyas silver and ThS staining. 
Although this sequence of events does not prove causality between Ab and tau aggregation, both proteins 
have been found to co-localise within the same neurons, suggesting a role for intracellular Ab in triggering 
tau pathology. Synaptic defects are observed in the hippocampus at 6 months in this model, which correlates 
with the presence of intracellular Ab. 
 
Models based on the PS19 line, expressing the P301S tau variant, have largely confirmed these findings. 
Crossing this line with the PDAPP mouse or the 5xFAD line has resulted in exacerbated tau pathology, 
whereas Ab deposition is not significantly affected (Hurtado et al., 2010; Saul et al., 2013). The 
5xFAD/PS19 model furthermore shows increased astrogliosis compared to the original transgenic lines, as 
well as increased loss of synapses and neuronal death (Saul et al., 2013). The PDAPP/PS19 mice have been 
used for detailed analysis of the spatial progression of tau pathology, which matches to some extent the 
Braak staging of AD (Hurtado et al., 2010). However, a limitation of the PS19 model and crosses thereof 
is their strong motor phenotype, which interferes with commonly used behavioural assays. 
 
Another triple transgenic model, TauPS2APP, has resulted from crossing the PS2APP line expressing the 
K670N/M671L APP variant and the N141I PSEN2, with the pR5 tau P301L strain (Grueninger et al., 2010). 
In contrast to the models described above, amyloid plaques and accumulations of phosphorylated tau 
develop in parallel in this model, and in the same regions of the hippocampus. Gallyas silver staining and 
immuno-EM confirmed that the deposits of tau are of fibrillar nature, and that structures resembling the 
paired helical filaments observed in AD are present within dendrites. Phosphorylation of S422 has been 
shown by means of highly specific antibodies to be significantly increased in the triple transgenic line, 
compared to the original tau model. However, the triple transgenic mice do not show signs of increased 
neuronal loss compared to wild-type controls, and perform similarly to the PS2APP strain in behavioural 
assays. 
 
PLB1 double mice have been generated by targeted knock-in of the APP K670N/M671L/V717I and tau 
P301L/R406W mutants (Platt et al., 2011), resulting in more moderate expression levels than in models 
generated by pronuclear injection, a process that leads to integration of multiple copies of the transgene. 
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This line has been subsequently crossed with a PSEN1 A246E strain (Borchelt et al., 1997) to generate the 
PLB1 triple mouse model (Platt et al., 2011). Despite the low levels of Ab in the triple strain, intracellular 
staining as well as a small number of extracellular ThS and Congo red positive plaques appear at 6 months 
of age in the hippocampus and cortex, and the number of plaques increases during ageing. Phosphorylated 
tau has been identified in the same brain regions from 6 months of age, but no evidence for mature tau 
tangles was found. Synaptic plasticity, together with social recognition and spatial memory, start to decline 
at the same age. Furthermore, glucose metabolism and sleep behaviour are altered in the PLB1 triple mice, 
as found in patients suffering from AD. Altogether, despite some discrepancies such as the relatively fast 
accumulation of phosphorylated tau, this less aggressive model recapitulates many features of the early 
phases of human AD. 
 
Although most studies using double and triple transgenic mice have shown a unidirectional relationship 
between APP/Ab expression and increased tau pathology, there is an example in which amyloid deposition 
is increased by mutant tau expression. In that work, Tg2576 expressing APP with the K670N/M671L 
Swedish mutation was crossed with a mutant tau line, tauVLW, containing G272V, P301L and R406W 
mutations (Figure 3H) (Pérez et al., 2005; Ribé et al., 2005). Not only does the expression of APPSwe lead 
to increased tau phosphorylation and accumulation in the sarkosyl-insoluble fraction (Pérez et al., 2005), 
but expression of the tau mutant also increases the numbers of amyloid plaques by up to 5-fold at 16 months 
of age (Ribé et al., 2005). The double transgenic animals also suffer from more pronounced neuronal loss 
than either APPSwe or tauVLW littermates (Ribé et al., 2005). 
 
The models discussed so far have been based on tau mutations found in FTDP-17 patients, or combinations 
thereof, and they typically display tau pathology in the single transgenic lines, albeit increased by 
expression of Ab. In a model combining wild-type human tau 0N3R with APP K670N/M671L/V717I and 
PSEN1 M146L, tau tangles are absent (Boutajangout et al., 2004). However, in addition to APP-stained 
and ubiquitin-stained dystrophic neurites, tau-positive dystrophic neurites are also found surrounding 
amyloid plaques in these triple transgenic mice. In these neurites, tau is recognised by a subset of phospho-
specific and conformation-specific antibodies, but is not fibrillar, as indicated from a lack of Gallyas or 
Congo red staining. Similar observations have been reported for the TAPP and 3xTg-AD mice, although in 
those models tau tangles do occur in more distant regions from the Ab plaques (Lewis et al., 2001; Oddo 
et al., 2003). Similarly, in a more recent model resulting from a cross of WT human tau 4R with APPswe 
and PSEN1 ∆exon9, no evidence was found for the formation of tau tangles, although the mice were only 
examined up to 10 months of age (Jackson et al., 2016). This model, however, displays increased plaque 
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counts and dystrophic neurites compared to the APP/PSEN1 mice, although no increase in neuronal loss or 
astrogliosis was observed. 
 
In contrast, another model based on human wild-type tau does feature the development of tangles. This 
model is the result of a cross between animals expressing APP ∆E693 (the Osaka mutant) and a tau construct 
comprising 3R and 4R isoforms (Umeda et al., 2014). APP ∆E693 is not associated with amyloid plaque 
formation, but generates high levels of Ab oligomers. These oligomers, detected by the 11A1 
conformational antibody, appear earlier in double transgenic mice than in the original APP line, being 
evident intracellularly in regions of the hippocampus and cerebral cortex at 6 months of age. Furthermore, 
hyperphosphorylated tau, recognised by AT8 and PHF1 antibodies, is formed more rapidly in the CA3 
region of the hippocampus and in the cortex in double transgenic animals, appearing between 6 and 12 
months. Tau tangles are present in the same regions as detected by Gallyas silver staining and EM from 18 
months of age onwards. Loss of synapses and neuronal death in the CA3 region are also increased in the 
double transgenic line, as are the memory deficits observed in the Morris water maze test. Altogether, 
whereas other models have failed to produce the full pathology of wild-type tau isoforms, the combination 
of tau with APP ∆E693 has had better success in doing so. This finding demonstrates that the presence of 
Ab plaques is not a prerequisite for tau pathology and neuronal dysfunction to occur, but Ab oligomers 
may be responsible for triggering this cascade instead. 
 
Taking advantage of the knock-in strategy described in Section 3.1 for the APP-based models, a recent 
study reports on the humanisation of the mouse MAPT gene (Saito et al., 2019). Whereas the subcellular 
distribution of human tau appears normal in this model, crossing it with the APP knock-in model, APPNL-
G-F, results in enhanced tau phosphorylation at several sites. Tau tangles were not identified, yet these more 
physiological models may prove useful for further studies into the relationship between Ab and tau 
pathology. 
 
Finally, it is worth noting that the spreading of tau pathology by means of neuronal connectivity has 
received much attention in recent years (Goedert, Eisenberg and Crowther, 2017; Jucker and Walker, 2018). 
In a model expressing the human P301L tau variant exclusively in layer II of the entorhinal cortex, it has 
been shown that this protein is present in synaptically connected neurons that do not express it, and that it 
seeds the aggregation of endogenous mouse tau (de Calignon et al., 2012). Crossing this line with the model 
that expresses APPswe and PSEN1 ∆exon9 has led to an increased spread of misfolded tau, and to increased 
neuronal loss in the entorhinal cortex where tau is expressed (Pooler et al., 2015). In addition, at 16 months 
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of age, the triple transgenic animals display more and larger Ab deposits in the entorhinal and 
somatosensory cortices, and more dystrophic neurites surrounding the plaques. 
 
In summary, although it has proved to be difficult to recapitulate the complex pathology and phenotype of 
human AD in rodent models, there has been significant progress towards this objective as a result of 
combining in a variety of ways transgenes for APP, presenilins and tau.   
 
 
3.4 a-Synuclein models 
 
Yeast models 
The first yeast model for PD, based on the expression of human a-synuclein in S. cerevisiae, was reported 
in 2003 (Figure 3B) (Outeiro and Lindquist, 2003). Expression of a single copy of GFP-tagged human a-
synuclein resulted in the localisation of the protein at lipid membranes, whereas expression of two copies 
caused it to form cytoplasmic inclusions containing lipid molecules, as shown by staining with the lipophilic 
dye Nile red, in addition to protein. Furthermore, a dose-dependent cytotoxicity was observed, consistent 
with a toxic gain of function associated with a-synuclein expression. Two familial a-synuclein mutants 
A30P and A53T were also investigated in this study. While the A53T mutant was found to display very 
similar behaviour to wild-type a-synuclein, the A30P mutant was shown to maintain a cytoplasmic 
distribution at single copy level, rather than accumulating at the lipid membrane, and to exhibit toxicity 
only when expressed from a high-copy plasmid (Outeiro and Lindquist, 2003). Subsequently, inclusions of 
A53T a-synuclein, either GFP-tagged or unlabelled, were shown to react with ThS, indicating an amyloid-
like structure, whereas staining was not observed in cells expressing the A30P mutant (Zabrocki et al., 
2005). These in vivo models (Table 2) have confirmed the importance of the interactions of a-synuclein 
with lipid membranes, and have provided insights into the correlation between inclusion formation, 
amyloid-like aggregation and cytotoxicity. 
 
Worm models 
The tendency of a-synuclein to accumulate into cytoplasmic inclusions was further corroborated in C. 
elegans models (Table 3). A model overexpressing yellow fluorescent protein (YFP)-tagged a-synuclein 
in the body wall muscle cells displays inclusions from day 1 of adulthood, and these increase in number as 
the worms age (van Ham et al., 2008). Interestingly, fluorescence recovery after photobleaching (FRAP) 
measurements (Table 1) have indicated that a-synuclein remains mobile within the inclusions, and only in 
 37 
old worms (from day 11 onwards) immobile inclusions, indicative of aggregated proteins, occur (van Ham 
et al., 2008). These results were confirmed recently by FLIM (Table 1), in which reduction of the 
fluorescence lifetime of the YFP tag, indicative of fibril formation by a-synuclein, is only observed after 
day 10 (Laine et al., 2019). However, motility defects are observed from day 4 onwards (van Ham et al., 
2008), suggesting that inclusion formation generates toxicity prior to the formation of detectable amyloid-
like aggregates. 
 
C. elegans has a particular advantage for PD research in that it contains eight dopaminergic neurons that 
can easily be tracked. Models overexpressing wild-type and mutant a-synuclein in dopaminergic neurons 
have been generated in several independent studies (Lakso et al., 2003; Cao et al., 2005; Kuwahara et al., 
2006). Although inclusions have only been found in a small fraction of neurons (Lakso et al., 2003; 
Kuwahara et al., 2006), or not at all (Cao et al., 2005), all studies report a loss of neuronal integrity. 
Expression of A53T and A30P, but not wild-type, a-synuclein was found to be associated with a loss of 
dendrites, in agreement with behavioural defects in food sensing, which depends on dopaminergic neurons 
(Kuwahara et al., 2006). This phenotype has been observed in 3-day old animals (Kuwahara et al., 2006), 
and in 4-day old animals in another study (Lakso et al., 2003), suggesting that neurotoxicity occurs 
relatively early in the lifespan of the animals. Furthermore, these studies suggest that a-synuclein 
neurotoxicity is not correlated with inclusion formation, but may be caused by the presence of smaller 
aggregates or soluble oligomeric species of a-synuclein. 
 
Fly models 
Expression of wild-type, A53T and A30P a-synuclein in the nervous system of Drosophila was found to 
lead to the formation of age-related Lewy body-like inclusions, correlated with the loss of dopaminergic 
neurons and impaired climbing function (Feany and Bender, 2000). In another model expressing the same 
a-synuclein variants specifically in the dopaminergic neurons, neuronal loss was also observed which could 
be restored by overexpression of the molecular chaperone Hsp70 (Auluck et al., 2002). Some controversy 
remains, however, about the extent of neuronal loss in fly models of PD, and other groups who used 
different methods have reported that the neurons might have been dysfunctional instead of lost (Pesah et 
al., 2005; Botella, Bayersdorfer and Schneuwly, 2008). The inclusions in the original model were examined 
by EM to reveal mostly round aggregates consisting of a rather homogeneous core, surrounded by radiating 
filaments (Feany and Bender, 2000). The model also displays diffuse aggregates and neuritic threads. 
Perhaps surprisingly, no differences between the phenotype of the wild-type and mutant a-synuclein lines 
have been found in this study (Feany and Bender, 2000). The severity of the phenotype may correlate better 
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with the a-synuclein expression levels, given that a more recent model achieving higher expression levels 
in the fly brain using the Q binary expression system shows exacerbated locomotory defects and a shortened 
lifespan, accompanied by a-synuclein inclusions that are mostly ubiquitin-positive, and vacuolar 
neurodegeneration (Ordonez, Lee and Feany, 2018). 
 
The relationship between a-synuclein aggregation and neurotoxicity has been further addressed by models 
expressing truncated or modified forms of the protein. A construct lacking part of the non-amyloid 
component (NAC) domain, which is essential for a-synuclein aggregation (Figure 2C), does not induce 
either inclusion formation or degeneration of dopaminergic neurons, whereas a more aggregation-prone C-
terminal truncation mutant shows increased deposition of proteins resistant to proteinase K (PK), as well 
as higher toxicity, supporting a direct correlation between a-synuclein aggregation and toxicity (Periquet 
et al., 2007). Notably, analysis by western blot has indicated that the levels of soluble oligomers are 
decreased in the NAC deletion flies, and increased in the C-terminal mutant line, leaving the question open 
as to whether the PK resistant species or the soluble oligomers are responsible for toxicity (Periquet et al., 
2007). 
 
Other studies have shown that the presence of large inclusions does not correlate with toxicity, and may 
even be protective. When phosphorylation of S129 is blocked by the mutation of serine to alanine, more 
inclusions are formed, correlating with more PK-resistant protein, but a reduced loss of dopaminergic 
neurons (Chen and Feany, 2005). How this observation relates to PD in humans is unclear, as S129-
phosphorylated a-synuclein is found in Lewy bodies (Fujiwara et al., 2002). However, a subsequent study 
has shown that S129 phosphorylation increases oligomer formation, explaining the exacerbated phenotype 
in the fly model, whereas phosphorylation at Y215 is protective, as blocking this modification results in 
increased oligomer levels and toxicity (Chen et al., 2009). 
 
The role of a-synuclein oligomers has been further addressed by designing proline mutants that prevent b-
strand formation in a-synuclein (Karpinar et al., 2009). These mutations have been found to inhibit fibril 
formation in vitro, yet increase the generation of oligomeric species. When expressed in C. elegans vulval 
muscles, wild-type a-synuclein-YFP forms elongated structures, whereas a triple proline mutant shows a 
diffuse localisation consistent with the absence of large aggregates (Karpinar et al., 2009). However, the 
triple proline mutant shows increased toxicity in both worm and fly models when expressed in 
dopaminergic neurons, supporting a role for a-synuclein oligomers in neurotoxicity (Karpinar et al., 2009). 
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Rodent and primate models 
As described above in the context of AD models, it has been challenging to develop a rodent model that 
recapitulates the main characteristic features of PD, including Lewy body pathology, specific loss of 
dopaminergic neurons in the substantia nigra, and loss of motor function. A complication arises from the 
fact that mice and rats express their endogenous forms of a-synuclein, which differ from the human form 
at seven residues, one of the differences being the A53T substitution, which in humans is associated with 
familial PD. Here, we discuss rodent models based on the transgenic expression of human a-synuclein, 
focusing on its misfolding and aggregation and the associated phenotypes (Table 5). For a more complete 
description, see (Fernagut and Chesselet, 2004; Dehay and Fernagut, 2016; Visanji et al., 2016), and for a 
discussion on models designed to study the spreading of a-synuclein pathology from cell-to-cell in a prion-
like fashion, which is thought to play a role in synucleinopathies, we refer to (Dehay et al., 2016). 
 
The first transgenic mouse model expressing human wild-type a-synuclein, which used the PDGF-b 
promoter, showed accumulation of the protein in several brain regions, including the neocortex, 
hippocampus and substantia nigra (Masliah et al., 2000). However, these inclusions did not resemble Lewy 
bodies, appearing in the nucleus as well as the cytoplasm, being associated with the ER, having a less well-
defined shape, and consisting of granular rather than fibrillar material. Use of the Thy1 promoter led to a 
different spatial expression pattern of wild-type a-synuclein (Rockenstein et al., 2002), and extensive 
characterisation of this model, termed Line 61, has revealed PK-resistant inclusions, phosphorylation of 
S129, reduced dopamine levels, and progressive PD-like symptoms including olfactory deficits and 
locomotory impairments, but no substantial neuronal loss (Chesselet et al., 2012). A model expressing 
A53T a-synuclein under control of the strong PrP promoter showed insoluble, fibrillar protein and 
inclusions that stain for ThS, in contrast to the wild-type protein (Giasson et al., 2002). At 8 months of age, 
the A53T mice start to develop motor defects, whereas wild-type a-synuclein transgenic mice are 
unaffected. However, the A53T phenotype is not associated with a loss of dopaminergic neurons in the 
substantia nigra in this model (Giasson et al., 2002). 
 
Conversely, other transgenic models led to degeneration of dopaminergic neurons in the substantia nigra 
but without the presence of observable inclusions, as exemplified by models expressing a combined A30P 
+ A53T mutant (Richfield et al., 2002; Thiruchelvam et al., 2004), and a C-terminally truncated construct 
(Wakamatsu et al., 2008), respectively. In a model expressing wild-type human a-synuclein from a 
bacterial artificial chromosome (BAC) construct that includes the native human regulatory sequences, 
defects in dopaminergic neurotransmission are accompanied by the presence of high molecular weight 
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soluble species, although PK-resistant aggregates have not been identified, suggesting that toxicity may 
arise from intermediate species along the aggregation pathway (Janezic et al., 2013). A mouse model with 
inducible A53T a-synuclein expression similarly shows high molecular weight species on western blots in 
the absence of large inclusions, which correlate with perturbations in the Golgi apparatus in midbrain 
dopaminergic neurons, as well as changes in lysosomal and autophagic markers (Lin et al., 2012). 
 
A recent mouse model was created following the hypothesis that native a-synuclein can occur as folded 
tetramers, such that a shift to the monomeric conformation puts the protein at risk of aggregation (Bartels, 
Choi and Selkoe, 2011; Dettmer et al., 2015). Overexpression of a triple mutant thought to disrupt the 
tetramers, referred to as 3K because of the three E-to-K substitutions, gives rise to a strong motor phenotype, 
selective degeneration of dopaminergic neurons in the substantia nigra, and abnormal accumulation of a-
synuclein co-localising with vesicles (Nuber et al., 2018). When compared at similar expression levels, the 
phenotype of the 3K mutant mice is stronger than that of a model expressing a BAC construct with the 
single E46K mutant that is found in some cases of familial PD. In addition, 3K is present in C-terminally 
truncated and S129 phosphorylated forms, and in older mice fibrillar material is present in the a-
synuclein/vesicle assemblies (Nuber et al., 2018), reminiscent of recent investigations showing that Lewy 
bodies contain vesicular structures (Shahmoradian et al., 2019)[Mahul-Mellier, Anne-Laure, et al. "The 
process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers 
of neurodegeneration." Proceedings of the National Academy of Sciences 117.9 (2020): 4971-4982.]. 
 
Applying the BAC approach to create transgenic rats has led to a model that also recapitulates these and 
other features of human PD (Nuber et al., 2013). Full-length as well as C-terminally truncated insoluble a-
synuclein accumulate as the rats age, following a similar development as that observed in the Braak stages 
of PD (Braak et al., 2003). PK-resistant inclusions are found in several brain regions including the 
substantia nigra, and the presence of aggregated protein has been further confirmed by dot blots using the 
FILA-1 antibody which recognises a-synuclein oligomers and fibrils but not monomers (Nuber et al., 
2013). Electron micrographs have shown inclusions containing lysosomes and lipid droplets, as well as 
accumulated vesicles at synaptic termini. In addition to the accumulation of a-synuclein, the phenotype of 
this rat model also recapitulates certain aspects of the course of PD in humans, with early changes in 
avoidance and novelty-seeking behaviour and defects in the sense of smell, followed by later motor 
symptoms, which correlate with the loss of dopaminergic neurons (Nuber et al., 2013). 
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Injection of a-synuclein constructs in lentiviral (LV) or recombinant adeno-associated viral (rAAV) vectors 
has been used as an alternative approach to generate high local concentrations of the protein in the substantia 
nigra and to induce rapid neurodegeneration specifically in this region. The majority of viral vector rat and 
mouse models displays a-synuclein accumulation in the cytoplasm as well as in dystrophic neurites, yet 
does not feature Lewy body-like pathology (Kirik et al., 2002; Lo Bianco et al., 2002; Chung et al., 2009; 
Dehay and Fernagut, 2016). However, PK-resistant a-synuclein and small ThS-positive inclusions have 
been observed in a rat rAAV model (da Silveira et al., 2009). a-Synuclein accumulates close to the nucleus, 
the ER and Golgi in this model, and some fibrillar structures were observed in electron micrographs to co-
localise with lysosomes and other vesicles. Interestingly, the number of ThS-positive inclusions was 
significantly increased when using the S129A a-synuclein mutation, which cannot be phosphorylated (da 
Silveira et al., 2009), an observation analogous to the results obtained in the Drosophila model (Chen and 
Feany, 2005). On the other hand, the phosphomimetic S129D mutation displays fewer, but larger ThS 
positive aggregates, whereas no difference in toxicity was found between the different phosphorylation 
states (da Silveira et al., 2009). However, another study using rat rAAV models reports that the non-
phosphorylatable S129A mutant causes more dopaminergic neurodegeneration, whereas S129D forms 
more inclusions, although the latter have not been examined ultrastructurally (Gorbatyuk et al., 2008). The 
precise role of S129 phosphorylation in a-synuclein aggregation and toxicity thus remains to be determined 
(Sato, Kato and Arawaka, 2013). 
 
Viral vector models have provided a unique means to assess the effect of varying a-synuclein 
concentrations on its aggregation and the time course of neurodegeneration following injection. The 
appearance of ThS positive a-synuclein A53T inclusions is dose-dependent and time-dependent in rats, and 
correlates with dopaminergic dysfunction (Van der Perren et al., 2015). Western blots have confirmed that 
insoluble and phosphorylated a-synuclein accumulates over time, and that high molecular weight 
oligomeric a-synuclein species are apparent at later time points after injection (Van der Perren et al., 2015). 
Using the same type of viral vector, a mouse model has also been established that displays Lewy body-like 
pathology and degeneration of dopaminergic neurons, phosphorylation of S129 and impairments in motor 
behaviour (Oliveras-Salvá et al., 2013). Both wild-type and A53T a-synuclein lead to similar levels of 
protein accumulation and loss of dopaminergic neurons using this approach. Another type of optimised 
rAAV vector has also been employed successfully in mice to express A53T a-synuclein locally leading to 
a robust phenotype, including the loss of dopaminergic neurons and reduced dopamine levels, accompanied 
by the formation of PK-resistant a-synuclein inclusions in cell bodies and dystrophic neurites, resembling  
PD pathology (Ip et al., 2017). 
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The success with rAAV vectors in rodents has led to the development of non-human primate models using 
the same technology, resulting in a marmoset model that features a-synuclein accumulation in the 
cytoplasm and neurites, as well as partial dopaminergic neurodegeneration and motor symptoms (Kirik et 
al., 2003). In a subsequent study, the monkeys were followed over a longer period of up to a year, leading 
to the discovery of ubiquitin-positive inclusions, which also occur in human PD (Eslamboli et al., 2007). 
Furthermore, animals injected with the A53T a-synuclein construct show stronger neurodegeneration 
compared to the wild-type protein and a worsened phenotype at later time points, potentially making this a 
useful model to test therapeutic strategies. 
 
 
4. Identification of biological pathways using in vivo models 
 
Several current disease models are successful in recapitulating key aspects of protein misfolding and 
aggregation, and exhibit toxic phenotypes, making them useful to interrogate disease mechanisms by 
identifying the perturbed cellular pathways. Excellent tools are available for commonly used model 
organisms to probe these questions at the systems level by means of genomic, transcriptomic and proteomic 
studies. 
 
Simple model organisms, including yeast, worms and flies, are amenable to large screens to identify genetic 
modifiers of protein aggregation and the associated toxicity. In addition, transcriptomics and proteomics 
can be applied to any organism of which the RNA or protein content can be extracted, to inform on the 
dysregulation of cellular pathways upon expression of the disease-related gene. Improvements in 
sequencing technologies have recently increased dramatically the scope of transcriptomics studies, which 
were previously limited to microarray analysis on a predefined set of genes, whereas genome-wide 
expression levels can now be determined routinely with high sensitivity and few artefacts using next 
generation sequencing methods such as RNAseq (Wang, Gerstein and Snyder, 2009; Breschi, Gingeras and 
Guigó, 2017). Similarly, developments in mass spectrometry and methods for data analysis have greatly 
enhanced the possibilities of performing comparative and quantitative proteomics to identify changes in 
protein abundance as well as posttranslational modifications (Bantscheff et al., 2012; Feng, Cappelletti and 
Picotti, 2017; Schubert et al., 2017). Not only have mass spectrometers improved in terms of sensitivity 
and resolution, but the opportunities for quantitative analysis of animal and human samples have expanded 
significantly by chemical labelling approaches such as tandem mass tags (TMTs) and isobaric tags for 
absolute and relative quantification (iTRAQ). Alternatively, label-free approaches based on counting the 
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number of peptide-to-spectrum matches for each protein have gained popularity. In addition, dedicated 
proteomic workflows exist that inform on protein-protein interactions and on protein conformations, 
although these methods are currently largely restricted to unicellular organisms and cultured cells (Minde, 
Dunker and Lilley, 2017). 
 
In this section, we highlight the key pathways and genes that have been identified using these various 
technologies in relation to protein misfolding in the organismal models of AD and PD (Tables 2-5). 
 
4.1 Biological pathways in Alzheimer’s disease models 
 
Yeast models 
Of the in vivo models described here, yeast is perhaps the most highly amenable to systematic analysis at 
the level of the genome, transcriptome and proteome. Extensive toolkits are available, and profiling of 
genetic interactions, mRNA expression levels, protein levels, metabolite levels, biological effects of small 
molecules, and phenotypic responses can be performed on a large scale fairly readily (Khurana and 
Lindquist, 2010). Although yeast does have a nervous system, or the secretase activity required for APP 
processing, it has been used to identify conserved genetic factors involved in Ab toxicity (Treusch et al., 
2011). The most potent suppressors of such toxicity were found to be genes involved in endocytosis, 
including the yeast homologue of PICALM, which is a known risk factor for AD as identified by genome 
wide association studies (GWAS). A number of these hits have been confirmed in a C. elegans model 
expressing Ab42 in glutamatergic neurons (Treusch et al., 2011). Microarray analysis revealed the 
induction of ER stress and downregulation of mitochondrial processes upon expression of Ab42 targeted 
to the secretory pathway (Chen et al., 2017). 
 
Worm models 
The main power of C. elegans in genetic screens is the ease with which RNA interference (RNAi) can be 
performed, simply by feeding the worms with bacteria expressing the relevant double stranded RNA 
(dsRNA). Libraries targeting 86% of all the annotated C. elegans genes are available and can be routinely 
screened if an appropriate read-out is available (Sin, Michels and Nollen, 2014). Performing RNAi by 
feeding is very efficient for certain tissues, such as intestinal and muscle cells, but works less well in 
neurons. With respect to Ab toxicity, C. elegans has been used for an RNAi screen specifically targeted at 
a conserved set of molecular chaperones (Brehme et al., 2014). Out of 219 molecular chaperone genes 
tested, knockdown of 18 led to increased paralysis rates in animals expressing Ab in the muscle cells. The 
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majority of these genes are also protective in worms expressing polyglutamine, the aggregation of which is 
linked to Huntington’s disease and a variety of other conditions, indicating that their effects may be related 
to a general improvement in protein homeostasis capacity (Brehme et al., 2014). Another RNAi screen in 
the C. elegans model expressing Ab in the muscle cells was targeted at genes with known human 
homologues, leading to the identification of various hits, including subunits of a vacuolar ATPase and of 
the ribosome, and a component of the TRiC/CCT chaperone (Khabirova et al., 2014). Mitochondrial 
function was furthermore shown to be impaired in a model expressing Ab42 in the neurons (Fong et al., 
2016), and metabolomics and transcriptomics subsequently demonstrated that early changes in tricarboxylic 
acid (TCA) cycle metabolism were underlying this phenotype (Teo et al., 2019). 
 
The link between Ab accumulation and the action of molecular chaperones was further supported by mass 
spectrometry, in a study where two Hsp70 proteins and three small heat shock proteins (sHSPs) were found 
to co-localise with Ab deposits in the body wall muscle cells of C. elegans (Fonte et al., 2002). In a study 
on an inducible C. elegans model expressing Ab in body wall muscle cells, gene expression changes 
assessed by RNA microarrays also include sHSPs and Hsp70, as well as mitochondrial unfolded protein 
response (UPR) genes and proteasomal factors. An aggregation-prone GFP variant was employed as a 
control in this study, enabling the identification of the genes that are differentially expressed specifically as 
a consequence of Ab-mediated toxicity, rather than resulting from protein aggregation in general (Hassan 
et al., 2015). The changes in gene expression resemble those induced by a pore-forming toxin, Cry5B, 
suggesting that Ab may exert its toxic effects in this model by affecting membrane integrity. 
 
In a genome-wide screen in C. elegans expressing mutant tau in neurons, molecular chaperones have been 
identified along with proteases, kinases and phosphatases, and a number of other enzymes, signalling 
proteins and DNA/RNA regulating factors (Kraemer et al., 2006). The identification of kinases and 
phosphatases is consistent with the known importance of tau phosphorylation in AD. However, RNAi 
knockdown of the C. elegans homologues of GSK3-b and MARK worsens the phenotype of the tau model, 
suggesting that the action of these kinases is beneficial, in contrast to their role in tau pathology in humans 
(Hanger, Anderton and Noble, 2009). 
 
Fly models 
Drosophila genetic screens are often based on screening for suppressors or enhancers of the rough eye 
phenotype caused by the expression of proteins that give rise to toxicity. Fly genetics have provided 
excellent tools for genome-wide studies, e.g. using randomly inserted transposable elements containing an 
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UAS (upstream activation sequence) that drives gene expression upon activation by the GAL4 protein, 
which can be expressed in a tissue-specific manner. Depending on the location and direction of insertion of 
the transposable element in the context of a gene, expression can either be enhanced or disrupted. Using 
this system, a screen has been performed on flies expressing Ab42 in the eye, leading to the identification 
of 23 modifier genes of which several have been confirmed by mutagenesis (Cao et al., 2008). Consistent 
with the role of these pathways in human disease, genes operating in the secretory pathway and involved 
in cholesterol metabolism were found, as well as genes regulating chromatin structure and function (Cao et 
al., 2008). In a complementary approach using a loss-of-function library, the gene Toll has been identified, 
which bears homology to the mammalian interleukin-1 receptor. Deletion of this gene or mutations in 
downstream signalling components ameliorate the rough eye phenotype and shorten the lifespan of the 
Ab42 flies, suggesting an important role of immune signalling in Ab42-mediated toxicity (Tan et al., 2008). 
 
A microarray transcriptomics study on flies expressing Ab42 throughout the nervous system revealed 
changes in pathways related to oxidative stress and the immune response (Favrin et al., 2013). Although 
these pathways are also altered during the ageing of control flies, several genes are affected specifically by 
the expression of Ab42, such as the superoxide dismutase gene Sod3 which is upregulated ~8-fold 
compared to controls. Further changes in the Ab42 flies include the upregulation of a gene involved in ER-
to-Golgi transport, and the downregulation of a putative ER molecular chaperone, consistent with the 
involvement of the secretory pathway in Ab42 toxicity (Favrin et al., 2013). 
 
Drosophila tau models have yielded a set of pathways related to toxicity that are different from those in the 
Ab models. Genetic screens using libraries of transposable element insertions led to the identification of 
phosphatases and kinases as modifiers of human tau toxicity in the fly eye (Shulman and Feany, 2003; 
Ambegaokar and Jackson, 2011), as well as diverse pathways including autophagy and lysosomal 
clearance, RNA processing, chromatin regulation, molecular chaperones and the cytoskeleton 
(Ambegaokar and Jackson, 2011). A RNAi screen on a tau R406W model also highlighted the role of the 
cytoskeleton, in particular dynein/dynactin mediated retrograde axonal transport, in addition to the activity 
of kinases and phosphatases, and protein metabolism (Butzlaff et al., 2015). Although the role of kinases 
and phosphatases seems obvious, given the relationship between the phosphorylation state of tau and its 
propensity to aggregate and cause toxicity, the genetic interactions were shown to be rather complex 
(Ambegaokar and Jackson, 2011). The phosphorylation state of tau, as probed with the AT8 antibody, does 
not correlate with either enhancers or suppressors of aggregation. Furthermore, reduced expression of the 
GSK3-b homologue is a potent suppressor not only of tau toxicity but also of that induced by Ab42 and 
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TDP-43, suggesting that the network of kinases and phosphatases may play a role in common mechanisms 
underlying neurodegeneration (Ambegaokar and Jackson, 2011).  
 
The Drosophila model based on tau V337M has been used to validate hits from GWAS performed on 
human AD patients. In one study, the relatively small number of participants did not produce statistically 
significant results, yet 6 out of 19 Drosophila homologues of candidate genes that were tested were shown 
to be modifiers of tau toxicity in the fly eye, including the glucose transporter SLC2A14 (Shulman et al., 
2011). In a follow-up study of a larger number of GWAS-identified loci, 9 out of 84 genes were confirmed 
to be modifiers of toxicity including two genes involved in cell adhesion, CD2AP and FERMT2 (Shulman 
et al., 2014). Thus, this screening strategy appears to have a high success rate compared to that of unbiased 
screens, and can validate GWAS results below the threshold for statistical significance. It will be interesting 
to see whether or not Drosophila models based on Ab42 can confirm the roles of additional associated 
genes. A limitation is, however, presented by human genes which do not have Drosophila homologues, 
such as those involved in lipid metabolism (APOE, CLU) and immunity (CR1, CD33 and MS4A) that are 
strongly associated with the risk of late-onset AD (Shulman et al., 2014). 
 
Rodent models 
Genetic screening for modifiers of protein misfolding is not commonly undertaken in rodents, but analysis 
of gene expression levels and of protein abundance have been applied extensively to mouse models of AD 
to shed light on the cellular pathways that are disturbed in response to protein aggregation. Especially in 
recent years, methods of analysing gene expression using novel sequencing technologies, as well as 
methods in mass spectrometry to detect protein levels and modifications, have greatly expanded these 
possibilities. 
 
A meta-analysis of the transcriptomes of aged and diseased humans versus mice has revealed that changes 
during ageing are relatively well-conserved between the two species, for example consistently showing 
upregulation of inflammatory factors (Hargis and Blalock, 2017). On the other hand, the gene expression 
profiles of mouse models of neurodegenerative diseases such as AD compared to healthy littermates display 
limited overlap with those of human patients (Burns et al., 2015; Hargis and Blalock, 2017), showing, for 
example, less downregulation of genes associated with mitochondrial function, protein degradation, RNA 
processing and DNA repair (Burns et al., 2015). Although the differences in gene expression between the 
animal models and human patients represent a major obstacle for the screening of drug candidates in 
preclinical trials, the models do allow perturbations in response to the misfolding of transgenically 
expressed proteins to be deciphered. Complementary insights into the dysregulation of cellular pathways 
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can be obtained from quantification of protein abundance, which does not always correlate directly with 
gene expression levels (Liu, Beyer and Aebersold, 2016), especially under conditions where protein quality 
control and turnover are perturbed. In the case of AD, transcriptomics and proteomics studies have together 
pointed towards a consistent set of dysregulated pathways in the various rodent models, including the 
immune response, mitochondrial function and synaptic transmission. 
 
Activation of the immune response is generally thought to be a direct reaction to the deposition of Ab 
plaques. In a comparative microarray analysis of brain tissue from Tg2576 and APPPS1 mice, the strongest 
change in gene expression was found to be a significant upregulation of the inflammatory factor 
progranulin, which was confirmed to be abundant in microglia and neurons in the vicinity of dense Ab 
plaques (Pereson et al., 2009). BRI-Ab42 mice similarly display progranulin immune-reactivity 
surrounding Ab plaques, suggesting a direct effect of extracellular plaque formation in triggering this 
immune response (Pereson et al., 2009).  
 
Another study has attempted to separate events resulting directly from Ab plaque formation from those 
caused by other sources of toxicity by comparing the gene expression pattern of two models, the 5xFAD 
model which has an aggressive phenotype with early onset Ab plaque formation, and a model expressing 
an N-terminal Ab truncated form (Ab4-42) that displays neuronal loss in the absence of Ab plaques (Bouter 
et al., 2014). Despite the different pathologies, both models suffer from age-related memory and learning 
defects of similar magnitudes. In that study, deep sequencing revealed that more than half of the 
differentially expressed genes in aged mice expressing Ab4-42 with respect to controls are similarly 
affected in the 5xFAD model, and that these are associated with in a broad range of biological functions 
including cell differentiation, neurogenesis, histone modification and transcription. Conversely, the 
majority of genes differentially expressed in the 5xFAD model compared to control mice are related to the 
immune response. These genes are not altered in the Ab4-42 mice, suggesting that these perturbations are 
a direct consequence of reactivity to Ab plaques in the 5xFAD model. Astrocytes are, however, activated 
in both models, as indicated by the upregulation of Gfap, encoding the typical marker glial fibrillary acidic 
protein (Bouter et al., 2014). 
 
Microarray analysis of the gene expression profile of the 5xFAD mouse model also showed changes in 
genes involved in the immune response, pointing towards activation of the complement system and of 
interferon-g regulated targets, concomitant with the appearance of pathological features including 
intracellular Ab42 accumulation, Ab plaque deposition and cognitive symptoms (Landel et al., 2014). A 
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mass spectrometric study specifically focusing on the activation of microglia has shown that levels of the 
cytokines IL1β and IL10 are elevated before widespread plaque deposition occurs (Boza-Serrano et al., 
2018). A combined proteomics and genomics study on the 5xFAD mouse has also revealed changes in the 
expression of genes related to immune function, prior to the onset of Ab plaque deposition (Bundy et al., 
2019). Other perturbations found in this study include the downregulation of proteins involved in the 
regulation of calcium binding, which show a trend in the same direction for mRNA and protein levels. 40% 
of the genes, however, were found to show an anticorrelation with their corresponding protein levels, 
underscoring the potential differences between gene expression levels and protein abundance, and the 
importance of complementing transcriptomics with proteomics. 
 
Given the evidence for a role of mitochondrial dysregulation in AD, a detailed proteomic analysis of 
mitochondria isolated from 3xTg mice has been performed, leading to the identification of 23 proteins that 
are either up- or downregulated compared to non-transgenic mice (Chou et al., 2011). These mitochondrial 
proteins have a variety of functions, including roles in metabolic processes such as oxidative 
phosphorylation but also functioning in ion transport, apoptosis and mitochondrial protein synthesis. The 
changes in protein levels are detectable in mice at 6 months of age, prior to widespread Ab plaque 
deposition and tau tangle formation, thus reflecting a perturbation in mitochondrial homeostasis early in 
the disease process (Chou et al., 2011). A similar approach on the APPPS1 mouse model has revealed 
changes in the levels of 60 mitochondrial proteins with roles in the electron transport chain, citric acid 
cycle, oxidative stress, and apoptosis, some of which are dysregulated prior to the onset of Ab plaque 
formation (Völgyi et al., 2017). 
 
An integrated proteomics and transcriptomics study on another APP/PSEN1 model took the approach of 
first investigating changes at the proteome level in different brain regions, followed by validation of the 
corresponding genetic pathways at the mRNA level (Kempf et al., 2016). Using mass spectrometry of 
peptides enriched in phosphorylation and glycosylation, changes in protein levels related to cytoskeleton-
based synaptic plasticity were found, and the mRNA levels of upstream regulators such as glutamatergic 
receptors and neurotrophic factors were shown to be affected accordingly. Using quantitative mass 
spectrometry on APP, APP/PSEN1 and Bri-Ab42 mice, proteins associated with late-onset AD were found 
to be altered, most notably ApoE, which was seen to be upregulated in all three models (Savas et al., 2017). 
Furthermore, proteins involved in excitatory synaptic transmission, in particular trafficking of the AMPA 
receptor, were found to be dysregulated, as well as mitochondrial proteins. 
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Several other reports have provided further evidence for the perturbation of synaptic plasticity at the 
proteome level. One study has specifically focused on the proteomic signature associated with memory 
defects, revealing an overlapping set of dysregulated membrane proteins involved in neuronal excitability 
and synaptic plasticity in the 5xFAD model of AD, as well as in aged control mice with memory impairment 
(Neuner et al., 2017). Changes in the cytoskeleton as well as in synaptic function have been reported for 
the olfactory bulb of an APP/PSEN1 mouse model, occurring around the same age when Ab plaques appear 
(Lachén-Montes et al., 2016). Levels of cytoskeletal proteins as well as chaperones have in addition been 
suggested to be modulated by the presence of Ab oligomers, as discovered in the APP ∆E693 mouse strain 
that accumulates oligomers rather than plaques (Takano et al., 2013). Finally, the McGill mutant APP rat 
model displays changes in proteins related to stress response and synaptic function at a young age before 
the onset of Ab plaques, whereas at later age metabolism (e.g. mitochondrial function and amino acid 
metabolism) becomes affected (Do Carmo et al., 2018). 
 
Analysis of the gene expression patterns of tau-based transgenic models has revealed important insights 
into the cellular responses towards tau aggregation. Transcriptional profiling of JNPL3 mice, which express 
tau P301L, revealed a down-regulation of anti-apoptotic factors, disturbances of microtubule-dependent 
intracellular trafficking, and down-regulation of a number of immune factors (Ho et al., 2001). A study on 
another tau P301L model used more stringent selection criteria to identify just one upregulated gene, 
encoding glyoxalase I (Chen et al., 2004). This enzyme functions in a pathway that prevents glycation and 
the formation of advanced glycated end products, which are known to occur in ageing and 
neurodegenerative disease. Glyoxalase I is strongly expressed in neurons with flame-shaped tau aggregates 
both in the mice and in AD patient brains, suggesting that it may be upregulated as a protective mechanism 
in response to protein aggregation (Chen et al., 2004).  
 
Changes in proteins functioning in metabolism, including mitochondrial proteins of the respiratory chain 
complex and detoxifiers of reactive oxygen species (ROS), as well as those with a role in synaptic 
transmission have furthermore been detected in a proteomic analysis of the tau P301L mouse model (David 
et al., 2005). Injecting Ab42 fibrils into the amygdala of the tau P301L model has been found to result in 
further imbalances in components of the cytoskeleton, metabolism, and synaptic transmission, as well as 
proteins functioning in stress response pathways and protein folding and degradation (David et al., 2006). 
Many of these changes have also been found in SHSY-5Y cells expressing tau P301L upon injection with 
Ab42 fibrils, suggesting conserved and rapid responses, whereas perturbations in the cytoskeleton and 
synaptic function appear exclusively in the mouse model, pointing towards longer-term or indirect 
consequences (David et al., 2006). Proteomic analysis of postsynaptic density isolated from tau P301S mice 
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has shown a depletion of GTPase-regulatory proteins, which could be related to the actin cytoskeletal 
defects and loss of dendritic spines that are observed in this model (Dejanovic et al., 2018). Consistent with 
many of these results, RNAseq of a more recent tau P301S mouse model has furthermore revealed 
perturbations in genes associated with presynaptic factors, glutamatergic signalling, and protein scaffolding 
(Ke et al., 2019). 
 
An additive effect of Ab and tau toxicity on mitochondrial dysfunction has been found in a triple mouse 
model, combining familial APP, PSEN2 and tau mutations (Rhein et al., 2009). Mitochondrial proteins 
including Complex I and Complex IV subunits are downregulated at the protein level in the triple mouse 
model more strongly than in the parental APP/PSEN2 or tau strains. In support of these findings, the 
respiratory function of isolated mitochondria was found to be reduced more drastically and at earlier age in 
the triple model compared to the APP/PSEN2 strain or wild-type animals (Rhein et al., 2009). 
 
Proteomic approaches have moreover been used to assess the misfolding and aggregation of endogenous 
mouse proteins, which may be triggered by the pressure on the protein homeostasis machinery caused by 
the aggregation of transgenic Ab and tau. Analysis of the SDS-insoluble fraction from mice expressing 
APP with Swedish mutations K670N/M671L and PSEN1 Δexon9 has shown the presence of cytosolic 
proteins including glycolytic enzymes and members of the 14-3-3 family of chaperones (Xu et al., 2013). 
In an independent study on the same mouse model using quantitative proteomics, mitochondrial proteins 
have been identified in the sarkosyl-insoluble fraction of aged mice (Thygesen et al., 2018). Finally, recent 
work on the inducible tau model rTg4510 has led to a set of SDS-insoluble proteins including kinases, other 
enzymes and chaperones that partially overlaps with that of the APP/PSEN1 model established using the 
same methods (Pace et al., 2018), suggesting a common mechanism that triggers the misfolding of 
otherwise soluble proteins. 
 
 
4.2  Biological pathways in Parkinson’s disease models 
 
Yeast models 
The genetic toolkit available for screens in yeast has been applied extensively to a-synuclein models, 
leading to the discovery of conserved cellular pathways involved in its toxicity. Early screens have made 
use of a genome-wide deletion library, showing an enrichment for genes involved in lipid metabolism and 
vesicle-mediated transport (Willingham et al., 2003). In accordance with the latter, a genome-wide 
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overexpression screen for suppressors and enhancers of a-synuclein toxicity identified the yeast homologue 
of human Rab1, a GTPase involved in ER-to-Golgi vesicle trafficking, as an important suppressor of 
toxicity. This protein is often found to co-localise with a-synuclein cytoplasmic inclusions, and its 
overexpression restores the trafficking defects associated with a-synuclein toxicity (Cooper et al., 2006). 
Yeast homologues of Rab3a and Rab8a, which function in synaptic and post-Golgi vesicle transport, 
respectively, have also been found associated with the inclusions in subsequent work, and overexpression 
of any one of these three Rab proteins rescues toxicity in C. elegans expressing a-synuclein in dopaminergic 
neurons (Gitler et al., 2008).  
 
In addition to defects in ER-to-Golgi trafficking, mitochondrial dysfunction has been identified in a 
transcriptional screen of a yeast strain with high a-synuclein expression levels, together with an increase in 
reactive oxygen species (ROS) (Su et al., 2010). A library screen on this model has revealed a group 
of 1,2,3,4-tetrahydroquinolinones capable of reducing a-synuclein foci formation and toxicity, in addition 
to re-establishing ER-to-Golgi trafficking as well as mitochondrial function, suggesting that these processes 
are tightly linked. These compounds are furthermore active in a C. elegans model and in rat primary neuron 
cultures, providing evidence for a conserved mechanism (Su et al., 2010). 
 
The role of vesicle trafficking has been confirmed once more in a study that made use of the high sensitivity 
to hydrogen peroxide of the yeast strain expressing a-synuclein (Liang et al., 2008). This study in addition 
reported ubiquitin-dependent protein degradation, protein biosynthesis, and stress response genes as 
suppressors of toxicity. The YPP1 gene was discovered as a suppressor specifically for the a-synuclein 
A30P mutant, and the encoded protein was shown to target a-synuclein to vacuoles for degradation (Flower 
et al., 2007). Findings of another overexpression screen using a large library of 5,500 strains, covering 85% 
of the yeast genome, are largely in agreement with the pathways previously mentioned, in addition pointing 
to a role for protein phosphorylation in the toxicity of a-synuclein (Yeger-Lotem et al., 2009). In this screen, 
the yeast homologue of human PARK9 was also identified, which encodes a lysosomal P-type ATPase that 
is mutated in a familial form of PD (Gitler et al., 2009). Overexpression of this gene suppresses a-synuclein 
toxicity not only in yeast, but also in a C. elegans model and in rat primary dopaminergic neurons. It also 
protects yeast cells against manganese-induced toxicity, a known risk factor for PD, providing a potential 
link between genetic and environmental factors in initiating the disease process (Gitler et al., 2009). Two 
other hits from this screen, an E3 ubiquitin ligase and a factor related to nitrosative stress, have later been 
validated in cortical neurons differentiated from patient-derived induced pluripotent stem cells (iPSCs) (C. 
Y. Chung et al., 2013). 
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Building on the results from genetic screens, a computational approach was designed with the aim of 
creating a genetic network underlying the disease phenotype, and of transposing it to the human 
homologues. Thus, a genetic map of a-synuclein toxicity has been created which spans the pathways 
identified previously, ranging from ER quality control and vesicle trafficking to calcium signalling and 
mitochondrial function, in which known genetic causes of familial PD appear in different parts of the 
network (Khurana et al., 2017). In an accompanying study that employs in situ peroxidase labelling coupled 
to mass spectrometry, the physical interaction partners of a-synuclein in rat primary cortical neurons were 
found to form a proteomic network that largely overlaps with the genetic network (Chung et al., 2017). 
Altogether, the yeast a-synuclein models in combination with available genomic and proteomic tools have 
generated remarkable results in understanding the processes underlying PD. 
 
Worm models 
In agreement with the findings in yeast, several independent genetic screens in C. elegans found 
components of vesicle trafficking pathways to be involved in a-synuclein accumulation and toxicity. A 
genome-wide RNAi screen for suppressors of inclusion formation in the C. elegans model expressing a-
synuclein in the body wall muscle cells revealed an enrichment of genes associated with the ER/Golgi and 
vesicle transport (van Ham et al., 2008). In a study targeting a subset of genes known or hypothesised to be 
involved in PD, two vesicle trafficking genes were discovered that protect against a-synuclein-mediated 
degeneration of dopaminergic neurons, in addition to known genetic PD factors such as DJ-1 and PINK1 
(Hamamichi et al., 2008). Finally, another screen performed on a pan-neuronal a-synuclein model led to 
the detection of several genes involved in endocytosis that protected against a-synuclein neurotoxicity, 
including two subunits of the adapter protein complex AP2 (Kuwahara et al., 2008). 
 
A gene that seemingly operates in a separate pathway that promotes aggregation was originally discovered 
in a screen targeting polyglutamine aggregation in the body wall muscle cells of C. elegans. This gene, 
moag-4 or SERF in humans, is similarly active in driving a-synuclein inclusion formation and toxicity, 
independently of known chaperone-dependent or insulin-signalling pathways (van Ham et al., 2010). 
Although the function of SERF in humans is not known at present, this gene may represent a suitable target 




Drosophila models of a-synuclein toxicity have been used less extensively in the context of unbiased 
genetic screens. Using the reduced levels of dopamine in the heads of flies expressing a-synuclein A53T 
as a read-out, in combination with a genome-wide deletion library, the mitochondrial chaperone TRAP1 
has been identified as a potent suppressor of toxicity (Butler et al., 2012). Overexpressing TRAP1 in the a-
synuclein A53T flies partially restores their climbing ability and resistance to oxidative stress, and the latter 
has been confirmed in rat neurons as well as in human cell lines, pointing towards a conserved link between 
a-synuclein pathology and mitochondrial dysfunction that is thought to play an important role in PD 
(Vicario et al., 2018). 
 
Rodent models 
Several transcriptomics and proteomics studies have been performed in recent years in rodent models for 
PD based on the transgenic expression of a-synuclein. One investigation was carried out on a cross of an 
A53T a-synuclein overexpression model and a knock-out strain of the mitochondrial kinase PINK1, which 
causes an enhanced phenotype with ubiquitinated a-synuclein inclusions in the spinal cord and basal brain 
in mice from one year of age, and a reduced lifespan (Gispert et al., 2015). Transcriptomic analysis of brain 
samples taken before the appearance of a-synuclein inclusions in this model has revealed perturbations in 
genes related to mitochondrial function, ubiquitin-mediated degradation, microtubule and vesicle 
trafficking, synaptic signalling and DNA-damage repair, compared to wild-type animals. At the protein 
level, analysis of ubiquitination patterns in 18-month-old mice has provided evidence for enhanced 
ubiquitination of a-synuclein itself upon the loss of PINK1, as well as reduced ubiquitination of the histone 
variant H2AX, a marker of sites of DNA-damage (Gispert et al., 2015). 
 
A quantitative proteomics study on the model expressing a-synuclein with both A30P and A53T mutations 
has also highlighted the role of mitochondrial dysfunction and oxidative stress in the substantia nigra, as 
well as impairment of the ubiquitin-proteasome system, and endoplasmic reticulum (ER) stress (Yan et al., 
2017). A useful data source was furthermore established by a detailed analysis of the protein levels in 
distinct regions of the mouse brain, which has been performed for both non-transgenic mice and the Line 
61 PD mouse model (S. Y. Jung et al., 2017). Comparison of the substantia nigra and an unaffected brain 
region in the PD model showed that membrane signalling proteins are upregulated specifically in the 
substantia nigra, whereas markers of extracellular matrix remodelling and inflammation are increased in 
aged PD mice compared to non-transgenic mice. 
 
Further studies at the systems level have mostly been performed on rodent models of PD induced by 
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treatment with neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which have 
been remarkably successful in recapitulating phenotypic aspects of human PD (Tieu, 2011; Kasahara et al., 
2017). Although these studies have identified perturbations in common pathways including oxidative 
phosphorylation, oxidative stress, apoptosis and synaptic transmission (Smith, 2009), a comparative meta-
analysis revealed that the gene expression signature of these models is relatively remote from that of human 
PD patients (Oerton and Bender, 2017). Overall, current animal models of PD provide useful tools to study 
certain aspects of the multi-factorial disease process, such as the interplay between mitochondrial 
dysfunction and a-synuclein aggregation, but need to be improved to recapitulate better the complexity of 
the disease in the human brain. 
 
5. Methodological challenges  
 
An essential aim of in vivo models of human disease is to enable preclinical studies on systems that 
recapitulate the pathological processes observed in patients. In this section we discuss four major 
challenges, two biophysical and two biological, that remain to be addressed in order to reach this goal: 
 
(1) To develop longitudinal detection methods for protein aggregates. In AD and PD drug discovery 
pipelines, preclinical studies in mouse models often rely on the post-mortem quantification of protein 
deposits using methods based on immunohistochemistry or amyloid-sensitive fluorescent dyes (Sevigny et 
al., 2016; Drummond and Wisniewski, 2017). Methods based on clearing techniques, including CLARITY 
(Chung and Deisseroth, 2013; K. Chung et al., 2013), 3DISCO (Ertürk et al., 2012) and Scale (Hama et al., 
2011) (Table 1), enable more quantitative assessments of the total amounts and distributions of these 
deposits, thereby offering more accurate endpoints on the anti-aggregation activities of therapeutic 
candidate compounds. 
 
One may expect even better readouts, however, by the further development of methods of monitoring 
longitudinally the inhibitory effects of these compounds. Approaches based on magnetic resonance imaging 
(MRI) and positron emission tomography (PET) (Table 1) (Weiner et al., 2013; Sevigny et al., 2016) offer 
already the possibility of carrying out this type of studies in mouse models. The development of PET tracers 
for a-synuclein will be particularly helpful in this direction (Merchant et al., 2019). 
 
 (2) To develop detection methods for protein oligomers. Both in AD and PD the most neurotoxic species 
are misfolded protein oligomers, and yet these species remain elusive and difficult to quantify, in 
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particularin in vivo models (Table 1). Immunohistochemistry is typically used to probe the accumulation 
of Ab, tau and a-synuclein in fixed samples, and conformation-specific antibodies are available for specific 
cases, including A11, which binds to b-sheet oligomers, and MC-1, which recognises misfolded tau. The 
recent introduction of ELISA-based methods of greatly enhanced sensitivity, such as SIMOA (Kuhle et al., 
2016), subject to further development, is opening novel opportunities in this direction. In our laboratory we 
have recently demonstrated the design of antibodies targeting specific epitopes (Sormanni, Aprile and 
Vendruscolo, 2015; Aprile et al., 2017)[Aprile et al. PNAS 2020 in press], and this approach holds promise 
for discriminating different populations of oligomeric species based on the accessibility of a range of 
epitopes. 
 
Advances in microscopy are furthermore expected to contribute to an improved molecular understanding 
of misfolded protein species in vivo. Super-resolution microscopy has revealed the morphology and the 
growth of fibrils at the nanometer scale in vitro and in cells (Kaminski Schierle, Van De Linde, et al., 2011; 
Duim et al., 2014; Pinotsi et al., 2016), and continuing efforts to implement these technologies in vivo have 
already allowed the use of RESOLFT and STED nanoscopy to visualise organelles and the cytoskeleton in 
C. elegans (Dreier et al., 2019), Drosophila (Schnorrenberg et al., 2016), and the mouse brain (Berning et 
al., 2012). Furthermore, the use of biosensors in combination with fluorescence microscopy may shed more 
light on the conformational state of protein aggregates in vivo, as demonstrated e.g. by the changes in the 
fluorescence lifetime of protein tags upon amyloid formation (Kaminski Schierle, Bertoncini, et al., 2011; 
Laine et al., 2019). 
 
Another approach that holds promise for the detection of oligomeric protein species in animal models and 
patient material relies on seeded amplification in vitro. Several assays, e.g. protein misfolding cyclic 
amplification (PMCA) (Saborio, Permanne and Soto, 2001), the amyloid seeding assay (Colby et al., 2007) 
and real-time quaking-induced conversion (RT-QuIC) (Atarashi et al., 2011) (Table 1), were originally 
designed to detect low concentrations of misfolded prion protein molecules, based on the conversion of 
PrPC to PrPSc by the addition of seeds of the latter species. These assays have been adapted successfully to 
enable the detection of misfolded a-synuclein (B. C. Jung et al., 2017; Shahnawaz et al., 2017) and tau 
(Meyer et al., 2014) in vitro, from mice and from human brain or cerebrospinal fluid (CSF). Further 
development of these approaches will undoubtedly help not only with the fundamental understanding of 
protein misfolding in vivo, but may also lead to diagnostic methods for patients. 
 
 (3) To create models to recapitulate the sporadic forms of AD and PD. The overexpression of Ab, tau 
and a-synuclein or their mutational variants provides models that recapitulate the familial forms of AD and 
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PD. In the sporadic forms, more subtle perturbations of the protein homeostasis system are probably at play, 
which result in the aggregation of the disease-associated proteins starting from normal expression levels. 
The creation of specific animal models is becoming technically more feasible with developments in genetic 
engineering techniques such as CRISPR/Cas9 (Knott and Doudna, 2018; Zhang, 2019), and by introducing 
additional genetic or environmental perturbations the need for the artificially high overexpression levels 
and non-physiological mutations on which current models often rely may be alleviated. For example, we 
have recently created a C. elegans model expressing Ab42 at single-copy levels in only two neurons, which 
displays small perturbations in neuronal signalling and may be useful to study the onset of disease 
symptoms triggered by additional sources of cellular stress (Sinnige et al., 2019). 
 
(4) To create models to recapitulate the complexity of human AD and PD brain tissues. The in vivo 
models that we have described in this review have the inevitable limitation that they are genetically non-
identical to humans, leading to differences in neuronal anatomy as well as processes such as ageing and the 
action of the immune system, which are critical in the study of neurodegenerative diseases. The use of 
iPSC-derived neurons and direct reprogramming of patient fibroblasts are promising approaches to 
circumventing some of these issues (Xu, Du and Deng, 2015; Engle, Blaha and Kleiman, 2018). In 
combination with 2D and 3D culturing methods, such as neuronal rosettes and brain organoids, respectively 
(Choi et al., 2014; Otani et al., 2016; Lancaster et al., 2017; Gonzalez et al., 2018), these systems may 
increasingly provide avenues to elucidate disease mechanisms and to screen for therapeutics, in parallel to 





The use of in vivo models is instrumental in obtaining a detailed understanding of human diseases by 
connecting the observed phenotypes to the underlying molecular processes that give rise to them. In this 
review we have described current in vivo models of Alzheimer’s and Parkinson’s diseases where the 
phenomenon of protein misfolding and aggregation plays a central role.  
 
Studies based on these models have shown that mature amyloid fibrils or large aggregate inclusions are 
generally relatively inert and not associated with cytotoxicity, as they are limited in their ability to engage 
in aberrant interactions. By contrast, aggregation intermediates such as oligomeric species formed by Ab, 
tau or a-synuclein are associated with the disturbance of cellular processes and with the onset and progress 
of neurodegenerative diseases. Some of the affected pathways appear to be disease-specific, as exemplified 
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by the association of vesicle trafficking and mitochondrial function with the misfolding of a-synuclein, and 
of cytoskeletal transport and protein phosphorylation with that of tau. Importantly, protein homeostasis 
becomes progressively impaired in ageing and neurodegeneration, and molecular chaperones have been 
shown to interact with all the three proteins discussed in this article, and to modulate their misfolding and 
aggregation. 
 
In perspective, however, the pathological mechanisms underlying these disorders are not yet fully 
understood, and no disease-modifying therapeutics have yet emerged. The creation of in vivo models that 
better recapitulate the sporadic forms of these diseases, as well as of accurate biophysical methods for the 
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Fig. 1. Mechanisms of amyloid formation in vitro. (a) In vitro ThT aggregation assay of Ab42 
at different starting monomer concentrations. The curves are fitted using a model that includes 
both primary and secondary nucleation. Figure adapted from (S. I. A. Cohen et al., 2013). (b) 
Schematic of the kinetic model of fibril formation including primary and secondary processes. 
Soluble monomeric forms of proteins undergo primary nucleation to generate oligomeric species 
that have the potential to convert into fibrils. The formation of fibrils is significantly enhanced by 
secondary processes that enable aggregates to proliferate by the further association of soluble 
protein molecules. The latter processes include fragmentation, which generates new fibril ends at 
which growth occurs, and surface catalysed nucleation, in which fibril surface functions as a 
template for the generation of new oligomeric and fibrillar species. Figure based on (S. I. A. Cohen 
et al., 2013). (c) ThT aggregation assay of α-synuclein in the presence of different concentrations 
of dimyristoylphosphatidylserine (DMPS) vesicles (black, 60 μM; purple, 120 μM; dark blue, 180 
μM; light blue, 240 μM; dark green, 300 μM; light green, 450 μM; yellow, 600 μM; orange, 1200 
μM). Figure adapted from (Galvagnion et al., 2015). (d) Schematic of the dominating mechanism 
of amyloid formation by α-synuclein in the presence of small unilamellar lipid vesicles, which 
present an interface for nucleation to occur. Figure based on (Galvagnion et al., 2015). 
 
 
Fig. 2. Schematic of Ab, tau and a-synuclein, and of the mutations that have been used in the 
models described in this article. (a) APP and its sequential processing into the Ab peptide by b-
secretase and g-secretase. Cleavage sites are indicated by the residue number at the N-terminal side 
of the cleavage; mutations are indicated with the residue numbers of full-length APP and those of 
the Ab40/42 cleavage product. Other APP processing pathways, such as α-secretase processing, 
and other Ab forms, such as Ab39 or Ab43, are omitted for clarity. (b) The MAPT gene encoding 
tau undergoes splicing to yield six possible isoforms. Shown is the full-length 2N4R tau isoform 
of 441 residues; 1N and 0N isoforms lack the second or both N-terminal inserts, respectively, and 
3R isoforms lack the second microtubule repeat (dashed boxes). The hexapeptide stretches 
VQIINK and VQIVYK, which have the propensity to form b-strands and are essential for the 
aggregation of tau, are located at the microtubule binding repeats. (c) Schematic of α-synuclein, 
containing three major regions: an N-terminal amphipathic domain with α-helical propensity 
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where several familial mutations are located (residues 1–61), a central hydrophobic part (residues 
61–95) known as the NAC region that is essential for amyloid formation, and an acidic C-terminal 
region (residues 95–140). 
 
 
Fig. 3. Examples of in vivo models of protein misfolding for the study of Alzheimer’s and 
Parkinson’s diseases. (a) The budding yeast S. cerevisiae is the most widely used eukaryotic 
model organism, featuring a conserved cellular organisation, including the nucleus and the 
secretory system. (b) The expression of two copies of human α-synuclein (either in the wild-type 
or the familial A53T and A30P forms) in S. cerevisiae leads to the formation of cytoplasmic puncta 
for the wild-type and A53T variants, but not for A30P; reproduced from (Outeiro and Lindquist, 
2003) with permission from Science. (c) The nematode worm C. elegans is a multicellular 
organism that consists of several tissues, such as a digestive system comprised of the pharynx and 
the intestine. (d) Left: C. elegans expressing Ab42 in the body wall muscle cells display deposits 
that can be stained with the amyloid-binding dye X-34. The head region of an Ab42-expressing 
animal is shown, with deposits indicated by arrows; asterisks mark unspecific staining of the mouth 
and intestine. Right: close-up of C. elegans expressing Ab42 in the two BAG neurons, stained 
with an anti-Ab antibody (green) and DAPI (blue). Adapted from (Sinnige et al., 2019). (e) The 
fruit fly D. melanogaster has a more complex brain than C. elegans, and possesses a compound 
eye that is often used as a read-out for toxicity. (f) The expression of Ab42, but not of Ab40, leads 
to the formation of ThS-positive deposits. Arrows indicate deposits; Kn: Kenyon cell layer; Ca: 
calyx. Reproduced from (Iijima et al., 2004); copyright 2004 National Academy of Sciences. (g) 
Rodent models are typically used for pre-clinical studies, but also provide a more complex system 
for fundamental studies of human disease mechanisms. (h) Overexpression in mice of human APP 
and tau with familial mutations leads to the formation of Ab deposits positive for ThS staining 
(left) and structures resembling tau tangles as visualised by Bielschowsky silver staining (right). 
The arrow in the left panel indicates a neuron. Reproduced from (Ribé et al., 2005) with permission 
from Elsevier. 
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Table 1: Commonly used biophysical methods for the study of protein misfolding in vivo and 
in vitro. The application of these methods to study protein aggregation and the associated 
references are mentioned throughout the main text. 
 
Methods and tools to probe protein misfolding and aggregation in vivo and in situ 
Amyloid binding dyes ThS, Congo red, NIAD-4, X-34, K114, luminescent conjugated 
oligothiophenes (LCOs), silver stain (tau tangles) 
Microscopy EM, immunohistochemistry, fluorescence microscopy including 
FLIM and FRAP 
Conformation-specific 
antibodies 
A11 (oligomers), MC1 (misfolded tau), TOC1 (tau oligomers), 
FILA-1 (a-synuclein oligomers), DesAbs (designed antibodies) 
Detergent solubility Sarkosyl, SDS 
Size determination SEC, sucrose gradient, SDS PAGE, western blot 
Visualisation of deposits CLARITY, 3DISCO, Scale, MRI, PET 
Biochemical assays ELISA, SIMOA, amyloid seeding assay, PMCA, RT-QuIC 
Methods to probe cellular pathways in vivo and in situ 
Genetic screens RNAi, random mutagenesis  
Transcriptomics RNA microarrays, next generation sequencing (RNAseq) 
Proteomics TMT, iTRAQ, label-free mass spectrometry 
Methods to probe protein aggregation in vitro 
Aggregation kinetics ThT fluorescence, quartz crystal microbalance, filter trap assay 
Secondary structure 
determination 
CD spectroscopy, FTIR spectroscopy 
Size/shape determination DLS, SEC-MALS, smFRET, SAXS, AFM, super-resolution 
microscopy 
3D structure determination Cryo-EM, solid-state NMR spectroscopy, X-ray diffraction 
 




Construct expressed Organismal 
phenotype 





Aβ42-Sup35p MRF not determined SDS-stable oligomers  heat shock response (Hsp104) (Bagriantsev and Liebman, 
2006) 
Aβ42-GFP and GFP-Aβ42 reduced growth 
rate 
punctate patches; co-localisation 
with lipids 
heat shock response (Caine et al., 2007) 




oligomers not resistant to boiling 
or SDS 
endocytosis (yeast PICALM) (Treusch et al., 2011) 




Oligomers  respiration, proteasomal 
degradation 
(Chen and Petranovic, 
2015) 
MFα-Aβ42-GFP WT and 
E22G 
reduced viability 
and growth rate 
accumulation in the secretory 
pathway 
membrane trafficking (yeast 
PICALM) 






tau 2N3R and 2N4R  no change in 
growth rate 
hyperphosphorylated and 
misfolded tau; small sarkosyl-
insoluble fraction 
phosphorylation (yeast GSK-3β and 
CDK5) 
(Vandebroek et al., 2005) 
tau 2N4R WT, P301L, 
G272V, N279K, ΔK280, 
V337M, R406W, S409E, 
S409A 
no change in 
growth rate 
phosphorylation of S409 increases 
sarkosyl-insoluble aggregates and 
higher order oligomers 
oxidative stress; mitochondrial 
dysfunction 







αsyn-GFP WT, A30P, 
A53T 
reduced growth 
rate at higher 
expression levels; 
less severe for 
A30P 
inclusions for WT and A53T co-
localising with ubiquitin; A30P 
diffusely distributed 
proteasomal degradation; lipid 
metabolism; ER-to-Golgi vesicle 
trafficking 
(Outeiro and Lindquist, 
2003) 
αsyn-GFP WT, A30P, 
A53T 
no reduction in 
growth rate or 
viability 
WT and A53T form inclusions at 
the plasma membrane; A53T 
inclusions are ThS positive; A30P 
diffuse 
lipid synthesis; proteasome; 
autophagy; endocytosis; oxidative 
stress 
(Zabrocki et al., 2005) 





WT and A53T but 
not A30P 
inclusions for WT and A53T but 
not for A30P; GST-fusions of WT 
and A30P form soluble oligomers 
heat shock response; proteasomal 
degradation 
(Dixon et al., 2005) 
GFP-αsyn WT, A30P, 
A53T 
reduced growth 
rate for all 3 
strains 
inclusions for WT and A53T but 
not for A30P 
heat shock response; oxidative 
stress; apoptosis 

























paralysis phenotype ThT and X-34 positive 
deposits, fibrils in EM 







paralysis phenotype ThT and X-34 positive 
deposits 
molecular chaperones (Hsp70, 
Hsp90, TRiC/CCT and others); 
lysosomal pathways (subunit of 
vacuolar ATPase); protein 
synthesis (ribosomal subunits) 
(McColl et al., 2012) 
Aβ3-42 with 
signal peptide 
neurons chemotaxis and learning 
impairments 
oligomeric species 
recognised by NU-4 
antibody 
  (Wu et al., 2006) 
Aβ1-42 with 
signal peptide 
neurons neuromuscular defects, 
reduced food sensing 
insoluble protein 
observed at old age 
metabolism, mitochondrial 
function 





neurodegeneration of the tail 
glutamatergic neurons  
ND   (Treusch et al., 2011) 
Aβ1-42 with 
signal peptide 
BAG neurons subtle modulation of 
behavioural response to CO2 
no ThT or X-34 
staining observed 






tau 1N4R WT, 
P301L and 
V337M 
neurons degeneration of axons, 
uncoordinated phenotype 









(Kraemer et al., 2003) 
tau 3R and 4R 
WT, 4R P301L 
and 4R R406W 
mechanosensory 
neurons 
WT slightly impaired touch 
response; mutants strong age-
related decline in touch 
response; neurodegeneration; 
loss of microtubules 
accumulation in cell 
bodies and neurites; no 
signs of aggregation 
kinases (GSK3); chaperones 
(Hsp70) 
(Miyasaka et al., 2005) 
tau 3R WT, 
PHP 
(phosphomimic) 
neurons partial uncoordinated 
phenotype and reduced 
thrashing; PHP more gaps in 
axons 
protein in detergent-
soluble but not 
insoluble fraction 
  (Brandt et al., 2009) 
tau 1N4R V337 
+ tau F3Δ280 
fragment 
neurons worsened locomotory 
phenotype and neuronal 
abnormalities compared to tau 
V337M alone; perturbed 
mitochondrial transport 





Aβ42 + tau 
F3Δ280 
fragment 
neurons shortened lifespan and worse 
defects in egg laying and 
chemotaxis compared to 
single transgenic lines; 
dopaminergic 
neurodegeneration 
more Congo Red 
positive deposits 
compared to single 
transgenic lines 











αsyn-YFP  body wall 
muscle cells 
motility defect cytoplasmic inclusions, 
largely mobile until old 
age 
vesicle trafficking; lipid 
metabolism 
(van Ham et al., 2008) 
αsyn-GFP body wall 
muscle cells 
not determined cytoplasmic inclusions  PD related pathways (pink, 
parkin); endolysosomal pathways; 
autophagy 
(Hamamichi et al., 
2008) 
αsyn WT, A53T neurons dopaminergic neuronal loss; 
motor deficit 
rare inclusions   (Lakso et al., 2003) 
αsyn WT dopaminergic 
neurons 





loss of dendrites and 




  (Kuwahara et al., 2006) 
αsyn WT, 
A53T, A30P 
neuronal no motility or development 
phenotype 




muscle cells not determined WT forms elongated 
structures; triple proline 
mutant remains diffuse 




























eye neurodegeneration of retina and 
neuropil of the optical lobe 
ThS positive deposits in retina and 
neuropil with a star-like appearance 
in EM 





neurons age-associated memory defects 
and neurodegeneration 
SDS stable Aβ oligomers; Aβ 
deposition in cortical layer 




neurons impaired climbing and memory; 
age-related neurodegeneration; 
developmental defects when 
raised at higher temperature 
Aβ deposition; punctate X-34 
positive deposits when raised at 
higher temperature 
  (Chakraborty et al., 
2011; Mhatre et al., 
2014) 
Aβ42* eye, neurons rough eye phenotype; 
locomotory and learning defects; 
shortened lifespan; 
neurodegeneration 




regulation of chromatin 
structure and function; 
immune response (Toll) 
(Finelli et al., 2004; 
Iijima et al., 2004) 
Aβ42 WT and 
E22G 
neurons rough eye phenotype; 
neurodegeneration; locomotor 
defects; shortened lifespan 
intracellular Aβ accumulation; 
diffuse extracellular deposits 
positive for oligomer antibody but 
not for Congo red; E22G forms 
SDS-resistant tetramers 
  (Crowther et al., 
2005) 
16 variants of 
Aβ42 
neurons locomotor defects and shortened 
lifespan 
not determined experimentally; 
good correlation between severity 
of phenotype and predicted 
aggregation propensity 




eye, neurons tandem Aβ42 causes rough eye 
phenotype and reduced lifespan; 
tandem Aβ40 no effect 
both form SDS-insoluble 
aggregates; tandem Aβ42 forms 
soluble oligomeric species 




neurons learning and locomotory defects; 
shortened lifespan 
intracellular ThS positive deposits; 
oligomers for WT and E22G 






locomotory defects; shortened 
lifespan; failed synaptic 
transmission; depletion of 
presynaptic mitochondria and 
synaptic vesicles 
accumulation in the cell bodies and 
axons 







shortened lifespan; age-related 
neurodegeneration 
misfolded and phosphorylated tau; 
no fibrils found 
protein phosphorylation; cell 
adhesion 






tau 2N4R WT 
+ GSK3-β 
eye neurodegeneration starting from 
larval stage 
flame shaped aggregates; PHFs and 
SFs in EM; tangles positive for 
phosphorylated tau 
autophagy and lysosomal 




(Jackson et al., 
2002) 
tau 0N4R WT glia reduced lifespan; increased 
apoptosis 
glial inclusions of phosphorylated, 
ThS and Bielschowsky silver 
positive tau; fibrils in sarkosyl-









neurons, glia various types of cellular stress inclusions of phosphorylated tau apoptosis; oxidative stress 
(JNK signalling); autophagy; 
unfolded protein response 









exacerbated abnormal axon 
morphology, locomotory defects 
and shortened lifespan compared 
to single transgenics 
stronger tau phosphorylation; 
aggregation not examined 
 













neurons Loss of dopaminergic neurons; 
climbing impairment 
Lewy body like round inclusions 
with radiating fibrils, thread and 
grain-like structures (EM) 
 






loss of dopaminergic neurons  Lewy body-like and Lewy neurite-
like staining; αsyn mostly soluble in 
high salt/ detergent buffer 
heat shock response (Hsp70) (Auluck et al., 
2002) 
αsyn WT neurons widespread neurodegeneration; 
reduced lifespan; locomotory 
defects 




neurons no neurodegeneration for Δ71-
82, slightly increased for 1-120 
Δ71-82 no inclusions, more PK 
sensitive protein and less oligomers 
than WT; 1-120 more inclusions 
and increased PK resistance 
compared to WT 
 




neurons S129A suppresses dopaminergic 
neuronal loss; S129D enhances 
retinal degeneration 
S129A more PK resistance, larger 
and more inclusions, more protein 
in sarkosyl-insoluble fraction; 
S192D similar to WT 
 





triple P mutant 
neurons triple P mutant reduces lifespan 
and motility most strongly; 
degeneration of dopaminergic 
neurons 
triple P mutant is predicted to 
increase the formation of oligomers 
A53T: mitochondrial 
proteostasis (TRAP1) 
(Karpinar et al., 
2009) 
 
* all Aβ40/42 expressed with signal peptide 
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PDAPP APP V717F dystrophic neurites and reactive astrocytes; 
synaptic loss and learning defects 
ThS-positive extracellular plaques starting 
from 6-9 months 
 
(Games et al., 1995) 
Tg2576 APP 
K670N/M671L 
dystrophic neurites and reactive astrocytes and 
microglia; impairment in Morris water maze 
ThS-positive plaques at 11-13 months, some of 
which are Congo red birefringent; soluble 
species Aβ*56 
immune response (progranulin); 
intracellular trafficking (Klc-1) 
(Hsiao et al., 1996) 
BRI-Aβ40/42 BRI-Aβ40/42 dystrophic neurites and reactive astrocytes 
around Aβ42 plaques, but no behavioural 
abnormalities 
ThS-positive plaques for Aβ42; deposits in 
blood vessels; no aggregation for Aβ40 
immune response (progranulin);  
Aβ and lipid metabolism (ApoE) 
(McGowan et al., 2005) 
PS2APP  APP 
K670N/M671L 
+ PSEN2 N141I  
dystrophic neurites and reactive astrocytes and 
microglia; mild deficiencies in synaptic plasticity 
and in Morris water maze 
congophilic Aβ plaques at 9 months  (Richards et al., 2003) 
APPSLPS1KI APP 
K670N/M671L/
V717I + PSEN1 
M233T/L235P  
neuronal loss in hippocampus; impairment in 
working memory and motor tasks  
ThS positive plaques and intracellular Aβ 
deposits 
 (Casas et al., 2004) 
APPPS1 APP 
K670N/M671L 
+ PSEN1 L166P 
dystrophic neurites and reactive glia; cognitive 
impairment at 8 months 
congophilic Aβ plaques starting from 6 weeks immune response (progranulin); 
mitochondrial function 






neuronal degeneration and loss; deficits in Y-
maze test at 4-5 months 
small and numerous ThS-positive plaques from 
2 months; intracellular Aβ puncta from 1.5 
months 
immune response; cell 
differentiation; neurogenesis; 
histone modification; transcription; 
regulation of calcium binding; 
synaptic plasticity 








neuroinflammation, synaptic alterations, memory 
impairment in Y-maze test 
Aβ plaques first observed at 6 months for NL-
F mice, and at 2 months for NL-G-F 







degenerating glutamatergic and cholinergic 
neurons surrounding plaques; learning and 
memory deficits at 3 months; limited neuronal 
loss at 18 months 
ThS positive plaques; intracellular Aβ 
accumulation; soluble trimeric Aβ species 
stress response; synaptic function; 
mitochondrial function; amino acid 
metabolism 





inflammation and phagocytosis of neuronal 
debris; significant neuronal loss; deficits in 
behavioural assays 
widespread ThS positive plaques at 16 months; 
intracellular Aβ 42; soluble oligomeric Aβ 
species; Gallyas silver tau aggregates 
 








htau genomic human 
tau in mouse tau 
knock-out 
background 
memory impairment; significant neuronal loss 
between 8 and 18 months 
phosphorylated and misfolded tau; fibrillar tau 
in somatodendritic compartments resembling 
pre-tangle state; PHFs in sarkosyl-insoluble 
fraction 
 




tau 1N4R WT abnormal axon morphologies and dystrophic 
neurites; slight motor impairment; memory 
deficit in Barnes maze  
phosphorylated and misfolded tau; low levels 
of oligomers; no tangles 
 
(Wheeler et al., 2015) 
JNPL3 tau 0N4R 
P301L  
motor and behavioural deficits tau tangles in brain and spinal cord that are 
phosphorylated and ThS, Congo red and 
Gallyas silver positive; fibrils in EM; sarkosyl-
insoluble material in aged mice 
anti-apoptotic factors; microtubule-
dependent intracellular trafficking; 
immune response 
(Lewis et al., 2000) 
pR5 tau 2N4R 
P301L 
reactive astrocytes; apoptotic neurons ThS and Gallyas silver positive tangles; 
granular accumulations of phosphorylated and 
misfolded tau; short fibrils in sarkosyl-
insoluble fraction 
advanced glycated end products 
(glyoxalase I); mitochondrial 
dysfunction and ROS; synaptic 
function 
(J. Götz et al., 2001) 
rTg4510 tau 0N4R 
P301L 
atrophy in cortex and hippocampus; impairments 
in Morris water maze test; locomotory deficits 
misfolded and hyperphosphorylated tau; 
tangles; sarkosyl insoluble material; fibrils 
seen by EM 
insolubility of kinases, enzymes, 
chaperones 
(Ramsden et al., 2005) 
PS19 tau 1N4R 
P301S 
activated microglia and astrocytes; neuronal 
inflammation; neurodegeneration 
phosphorylated and insoluble tau; ThS, Congo 




(Yoshiyama et al., 2007) 
TauΔK280 tau 2N4R 
ΔK280 
synaptic loss misfolded and phosphorylated tau; partially 
insoluble tau; tangles at old age 
 





astrogliosis; loss of synapses and neurons hyperphosphorylated and insoluble tau; 
Gallyas silver positive tangles; fibrils in 
sarkosyl-insoluble fraction 
 
(Mocanu et al., 2008) 
htau40AT tau 2N4R 
A152T 
reactive astrocytes and microglia; loss of 
synapses and neurons; neuronal 
hyperexcitability; memory deficits 
hyperphosphorylated, misfolded tau; Gallyas 
silver and ThS positive tangles; sarkosyl-
insoluble tau 
autophagy and lysosomal pathways (Decker et al., 2016; 
Sydow et al., 2016) 
hTau-A152T tau 1N4R 
A152T 
reactive astrocytes; behavioural deficits; 
neuronal hyperexcitability; age-related neuronal 
loss 
misfolded, soluble tau 
 




tau 3R residues 
151-391 
shortened lifespan; no neuronal loss phosphorylated, misfolded and sarkosyl-
insoluble tau; ThS and Congo Red positive 
tangles 
 


















+ tau 0N4R 
P301L 
inflammation and dystrophic neurites 
surrounding Aβ plaques as in Tg2576; motor 
symptoms as in JNPL3 
increased tau tangles compared to JNPL3; no 
change in Aβ deposition 
 
(Lewis et al., 2001) 
3xTg-AD  APP 
K670N/M671L
+ tau 0N4R 
P301L + PSEN1 
M146V 
synaptic dysfunction intracellular Aβ followed by plaques; 
misfolded and hyperphosphorylated tau; ThS 
and Gallyas silver positive tau tangles 
oxidative phosphorylation; ion 
transport; apoptosis; mitochondrial 
protein synthesis 
(Oddo et al., 2003) 
PDAPP/PS19  APP V717F + 
tau 1N4R 
P301S 
stronger motor phenotype and reduced lifespan 
compared to PS19 
spread of hyperphosphorylated tau in brain 
regions following Braak staging; accelerated 
formation of ThS positive tau tangles 
compared to PS19 
 
(Hurtado et al., 2010) 





+ tau 1N4R 
P301S 
increased inflammation, loss of synapses and  
neuronal death compared to PS19 or 5xFAD 
increased hyperphosphorylated and misfolded 
tau compared to PS19 
 
(Saul et al., 2013) 
TauPS2APP APP 
K670N/M671L 
mild cognitive impairment; no observable 
neuronal damage or loss 
accumulation of SDS-stable Aβ species as in 
PS2APP; phosphorylated tau spreading with 
oxidative phosphorylation (Rhein et al., 2009; 
Grueninger et al., 2010) 
 100 
+ PSEN2 N141I 
+ tau 2N4R 
P301L 
age; Gallyas silver positive tau tangles; PHF-
like fibrils in EM 
PLB1 triple APP 
K670N/M671L/
V717I + PSEN1 
A246E + tau 
P301L/R406W 
impaired synaptic plasticity; cognitive defects; 
altered glucose metabolism; sleep disturbances 
ThS and Congo Red positive Aβ plaques; 
phosphorylated tau starting at the same age of 
6 months 
 
(Platt et al., 2011) 
APPswe/tauVLW APP 
K670N/M671L 
+ tau 2N4R 
G272V/P301L/
R406W  
more neuronal loss than single transgenic lines increased tau phosphorylation and 
accumulation in sarkosyl-insoluble fraction 
compared to tauVLW; increased plaque load 
compared to Tg2576 
 
(Pérez et al., 2005; Ribé 
et al., 2005) 
tau/PS1/APP APP 
K670N/M671L/
V717I + PSEN1 
M146L + tau 
0N3R WT 
dystrophic neurites; inflammation phosphorylated tau surrounding Aβ plaques 
but no tangles 
 






+  PSEN1 
∆exon9 + tau 
0N4R WT 
more dystrophic neurites compared to APP/PS1 
but no increased loss of synapses or neurons 
increased area of ThS positive amyloid 
deposits; misfolded and phosphorylated tau but 
no tangles 
 
(Jackson et al., 2016) 
APPOSK-
Tg/tau264 
APP Δ693 + tau 
3R/4R WT 
accelerated synaptic loss, memory impairment 
and neuronal loss compared to single transgenic 
lines 
intracellular and oligomeric Aβ; 
phosphorylated tau; Gallyas positive tau 
tangles; fibrillar tau in EM 
 








no effect on inflammation or memory compared 
to AppNL-G-F model 
accelerated phosphorylation of tau compared to 
MAPT knock-in only, but no tangles 





+  PSEN1 
∆exon9 + tau 
0N4R P301L 
increased neurodegeneration and neuronal loss increased spread of misfolded tau from the 
entorhinal cortex to distal brain regions; more 
amyloid plaques than in APP/PS1 
 










Line D αsyn WT loss of dopaminergic neuron terminals in 
striatum; motor defect 
nuclear, ER-associated and cytoplasmic 
granular inclusions 
 
(Masliah et al., 2000) 
Line 61 αsyn WT loss of dopamine; motor symptoms; olfactory 
deficits 
PK-resistant inclusions membrane signalling (GnaI, 
Pde10a, Itpr1); extracellular matrix 
remodelling and inflammation 
(Hspg2, Lama5, and Lamb2) 
(Rockenstein et al., 
2002) 
M83 αsyn A53T motor defects; no loss of dopaminergic neurons fibrillar and ThS-positive protein 
 
(Giasson et al., 2002) 
hm2α-SYN αsyn A30P + 
A53T 
locomotory defects; loss of dopaminergic 
neurons 
no cytoplasmic inclusions identified mitochondrial function and 
oxidative stress; ubiquitin-
proteasome system; ER stress 
(Richfield et al., 2002) 
Syn130m αsyn WT 1-130 specific loss of dopaminergic neurons in 
substantia nigra, presumably during 
development 
no LB-like structures identified by different 
staining methods or western blot 
 
(Wakamatsu et al., 2008) 
SNCA-OVX genomic αsyn 
WT 
locomotory defects; loss of dopaminergic 
neurons; reduced dopamine release; increased 
clustering of vesicles at dopaminergic synapses 
high-molecular weight species but no PK 
resistant protein 
 




αsyn A53T locomotory defects; loss of dopaminergic 
neurons; reduced dopamine release; 
fragmentation of Golgi apparatus 
inclusions found at axons and in vacuolar 
structures in dopaminergic neurons 
lysosomal and autophagic pathways (Lin et al., 2012) 
3K genomic αsyn 
E35K + E46K + 
E61K 
progressive locomotory defects; dopaminergic 
neurodegeneration; partially restored with L-
DOPA 
granular inclusions of PK-resistant αsyn with 
S129 phosphorylation and C-terminal 
truncation; co-localisation with vesicles at 
synaptic terminals; lipid-rich accumulation 
 






changes in novelty-seeking and avoidance 
behaviour; reduced sense of smell; locomotory 
defects; dopaminergic neurodegeneration 
accumulation of insoluble and PK-resistant 
protein; C-terminally truncated αsyn in 
insoluble fraction 
 
(Nuber et al., 2013) 
 
